Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549



FORM 10-Q

(Mark One)    
ý   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended March 31, 2009

Or

o

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                        to                         

Commission File No. 1-6639

MAGELLAN HEALTH SERVICES, INC.
(Exact name of registrant as specified in its charter)

Delaware   58-1076937
(State or other jurisdiction of
incorporation or organization)
  (IRS Employer
Identification No.)

55 Nod Road, Avon, Connecticut

 

06001
(Address of principal executive offices)   (Zip code)

(860) 507-1900
(Registrant's telephone number, including area code)



        Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding twelve months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ý    No o

        Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of "accelerated filer and large accelerated filer" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ý   Accelerated filer o   Non-accelerated filer o
(Do not check if a smaller
reporting company)
  Smaller reporting company o

        Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes o    No o

        Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o    No ý

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
PROCEEDINGS DURING THE PRECEDING FIVE YEARS:

        Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes ý    No o

        The number of shares of the registrant's Ordinary Common Stock outstanding as of March 31, 2009 was 35,296,577.


Table of Contents

FORM 10-Q

MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

INDEX

 
   
  Page No.  

PART I—Financial Information:

       

Item 1:

 

Financial Statements

    3  

 

Condensed Consolidated Balance Sheets—December 31, 2008 and March 31, 2009

    3  

 

Condensed Consolidated Statements of Income—For the Three Months Ended March 31, 2008 and 2009

    4  

 

Condensed Consolidated Statements of Cash Flows—For the Three Months Ended March 31, 2008 and 2009

    5  

 

Notes to Condensed Consolidated Financial Statements

    6  

Item 2:

 

Management's Discussion and Analysis of Financial Condition and Results of Operations

    19  

Item 3:

 

Quantitative and Qualitative Disclosures About Market Risk

    32  

Item 4:

 

Controls and Procedures

    33  

PART II—Other Information:

       

Item 1:

 

Legal Proceedings

    34  

Item 2:

 

Unregistered Sales of Equity Securities and Use of Proceeds

    34  

Item 3:

 

Defaults Upon Senior Securities

    35  

Item 4:

 

Submission of Matters to a Vote of Security Holders

    35  

Item 5:

 

Other Information

    35  

Item 6:

 

Exhibits

    35  

Signatures

    36  

2


Table of Contents


PART I—FINANCIAL INFORMATION

Item 1.    Financial Statements.

        

MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except per share amounts)

 
  December 31,
2008
  March 31,
2009
 
 
   
  (unaudited)
 

ASSETS

             

Current Assets:

             

Cash and cash equivalents

  $ 211,825   $ 178,282  

Restricted cash

    192,395     128,039  

Accounts receivable, less allowance for doubtful accounts of $1,915 and $1,689 at December 31, 2008 and March 31, 2009, respectively

    82,076     84,312  

Short-term investments (restricted investments of $116,112 and $143,422 at December 31, 2008 and March 31, 2009, respectively)

    225,372     243,126  

Deferred income taxes

    58,092     58,092  

Other current assets (restricted deposits of $17,769 and $16,896 at December 31, 2008 and March 31, 2009, respectively)

    52,660     43,994  
           

Total Current Assets

    822,420     735,845  

Property and equipment, net

    88,436     84,615  

Long-term investments—restricted

    8,527     18,747  

Deferred income taxes

    76,769     71,488  

Other long-term assets

    3,472     3,604  

Goodwill

    367,325     367,325  

Other intangible assets, net

    50,615     48,474  
           

Total Assets

  $ 1,417,564   $ 1,330,098  
           

LIABILITIES AND STOCKHOLDERS' EQUITY

             

Current Liabilities:

             

Accounts payable

  $ 21,527   $ 24,651  

Accrued liabilities

    96,533     71,649  

Medical claims payable

    155,860     142,875  

Other medical liabilities

    99,953     88,504  

Current maturities of long-term debt and capital lease obligations

    8     7  
           

Total Current Liabilities

    373,881     327,686  

Long-term debt and capital lease obligations

    20     14  

Deferred credits and other long-term liabilities

    135,590     134,875  
           

Total Liabilities

    509,491     462,575  
           

Preferred stock, par value $.01 per share

             

Authorized—10,000 shares—Issued and outstanding—none

         

Ordinary common stock, par value $.01 per share

             
 

Authorized—100,000 shares at December 31, 2008 and March 31, 2009—Issued and outstanding—40,873 shares and 40,963 shares at December 31, 2008 and March 31, 2009, respectively

    409     410  

Multi-Vote common stock, par value $.01 per share

             
 

Authorized—40,000 shares—Issued and outstanding—none

         

Other Stockholders' Equity:

             

Additional paid-in capital

    589,011     597,017  

Retained earnings

    449,252     462,812  

Warrants outstanding

    5,382     5,382  

Accumulated other comprehensive income (loss)

    172     (114 )

Ordinary common stock in treasury, at cost, 3,867 shares and 5,666 shares at December 31, 2008 and March 31, 2009, respectively

    (136,153 )   (197,984 )
           

Total Stockholders' Equity

    908,073     867,523  
           

Total Liabilities and Stockholders' Equity

  $ 1,417,564   $ 1,330,098  
           

See accompanying notes to condensed consolidated financial statements.

3


Table of Contents


MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME
FOR THE THREE MONTHS ENDED MARCH 31,

(Unaudited)

(In thousands, except per share amounts)

 
  2008   2009  

Net revenue

  $ 650,290   $ 619,515  
           

Cost and expenses:

             
 

Cost of care

    454,074     431,718  
 

Cost of goods sold

    46,824     52,072  
 

Direct service costs and other operating expenses(1)

    109,748     103,064  
 

Depreciation and amortization

    14,374     11,043  
 

Interest expense

    1,215     427  
 

Interest income

    (5,493 )   (2,311 )
           

    620,742     596,013  
           

Income from continuing operations before income taxes

    29,548     23,502  

Provision for income taxes

    12,304     9,942  
           

Net income

    17,244     13,560  

Other comprehensive loss

    (14 )   (286 )
           

Comprehensive income

  $ 17,230   $ 13,274  
           

Weighted average number of common shares outstanding—basic (See Note B)

    39,736     36,208  
           

Weighted average number of common shares outstanding—diluted (See Note B)

    40,340     36,386  
           

Net income per common share—basic:

  $ 0.43   $ 0.37  
           

Net income per common share—diluted:

  $ 0.43   $ 0.37  
           

(1)
Includes stock compensation expense of $12,018 and $6,432 for the three months ended March 31, 2008 and 2009, respectively.

See accompanying notes to condensed consolidated financial statements.

4


Table of Contents


MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE THREE MONTHS ENDED MARCH 31,

(Unaudited)

(In thousands)

 
  2008   2009  

Cash flows from operating activities:

             

Net income

  $ 17,244   $ 13,560  

Adjustments to reconcile net income to net cash provided by operating activities:

             

Depreciation and amortization

    14,374     11,043  

Non-cash interest expense

    573     232  

Non-cash stock compensation expense

    12,018     6,432  

Non-cash income tax expense

    10,586     4,639  

Cash flows from changes in assets and liabilities, net of effects from acquisitions of businesses:

             

Restricted cash

    (10,435 )   64,356  

Accounts receivable, net

    (15,063 )   (2,236 )

Other assets

    4,997     8,297  

Accounts payable and accrued liabilities

    (15,778 )   (23,813 )

Medical claims payable and other medical liabilities

    (5,532 )   (24,434 )

Other

    (537 )   568  
           

Net cash provided by operating activities

    12,447     58,644  
           

Cash flows from investing activities:

             

Capital expenditures

    (7,979 )   (5,310 )

Acquisitions and investments in businesses, net of cash acquired

    (425 )    

Purchase of investments

    (35,013 )   (77,730 )

Maturity of investments

    53,130     48,757  
           

Net cash provided by (used in) investing activities

    9,713     (34,283 )
           

Cash flows from financing activities:

             

Payments on long-term debt and capital lease obligations

    (4,307 )   (2 )

Payments to acquire treasury stock

        (59,476 )

Proceeds from exercise of stock options and warrants

    4,010     912  

Other

    (1,456 )   662  
           

Net cash used in financing activities

    (1,753 )   (57,904 )
           

Net increase (decrease) in cash and cash equivalents

    20,407     (33,543 )

Cash and cash equivalents at beginning of period

    312,372     211,825  
           

Cash and cash equivalents at end of period

  $ 332,779   $ 178,282  
           

See accompanying notes to condensed consolidated financial statements.

5


Table of Contents


MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2009

(Unaudited)

NOTE A—General

Basis of Presentation

        The accompanying unaudited condensed consolidated financial statements of Magellan Health Services, Inc., a Delaware corporation ("Magellan"), include the accounts of Magellan, its majority owned subsidiaries, and all variable interest entities ("VIEs") for which Magellan is the primary beneficiary (together with Magellan, the "Company"). The financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the Securities and Exchange Commission's (the "SEC") instructions to Form 10-Q. Accordingly, the financial statements do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments, consisting of normal recurring adjustments considered necessary for a fair presentation, have been included. The results of operations for the three months ended March 31, 2009 are not necessarily indicative of the results to be expected for the full year. All significant intercompany accounts and transactions have been eliminated in consolidation.

        These unaudited condensed consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements for the year ended December 31, 2008 and the notes thereto, which are included in the Company's Annual Report on Form 10-K filed with the SEC on February 27, 2009.

Business Overview

        The Company is engaged in the specialty managed healthcare business. Through 2005, the Company predominantly operated in the managed behavioral healthcare business. During 2006, the Company expanded into radiology benefits management and specialty pharmaceutical management as a result of certain acquisitions. The Company provides services to health plans, insurance companies, corporations, labor unions and various governmental agencies. The Company's business is divided into the following five segments, based on the services it provides and/or the customers that it serves, as described below.

Managed Behavioral Healthcare

        Two of the Company's segments are in the managed behavioral healthcare business. This line of business generally reflects the Company's coordination and management of the delivery of behavioral healthcare treatment services that are provided through its contracted network of third-party treatment providers, which includes psychiatrists, psychologists, other behavioral health professionals, psychiatric hospitals, general medical facilities with psychiatric beds, residential treatment centers and other treatment facilities. The treatment services provided through the Company's provider network include outpatient programs (such as counseling or therapy), intermediate care programs (such as intensive outpatient programs and partial hospitalization services), inpatient treatment and crisis intervention services. The Company generally does not directly provide, or own any provider of, treatment services except as relates to the Company's contract to provide managed behavioral healthcare services to Medicaid recipients and other beneficiaries of the Maricopa County Regional Behavioral Health Authority (the "Maricopa Contract"). Under the Maricopa Contract, effective August 31, 2007 the

6


Table of Contents


MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

March 31, 2009

(Unaudited)

NOTE A—General (Continued)


Company was required to assume the operations of twenty-four behavioral health direct care facilities for a transitional period and to divest itself of these facilities over a two year period. During March 2009, the Company began the operation of two additional behavioral health direct care facilities. At various dates in 2008 and 2009, the Company entered into agreements with three separate Provider Network Organizations ("PNOs") to transition 20 of the 26 behavioral health direct care facilities to the PNOs over various dates. Fourteen of such direct care facilities have been transitioned through April 2009 and the Company expects to divest itself of the remainder of these facilities before August 31, 2009.

        The Company provides its management services primarily through: (i) risk-based products, where the Company assumes all or a substantial portion of the responsibility for the cost of providing treatment services in exchange for a fixed per member per month fee, (ii) administrative services only ("ASO") products, where the Company provides services such as utilization review, claims administration and/or provider network management, but does not assume responsibility for the cost of the treatment services, and (iii) employee assistance programs ("EAPs") where the Company provides short-term outpatient behavioral counseling services.

        The managed behavioral healthcare business is managed based on the services provided and/or the customers served, through the following two segments:

        Commercial.    The Managed Behavioral Healthcare Commercial segment ("Commercial") generally reflects managed behavioral healthcare services and EAP services provided under contracts with managed care companies, health insurers and other health plans for some or all of their commercial, Medicaid and Medicare members, as well as with employers, including corporations and governmental agencies, and labor unions. Commercial's contracts encompass risk-based, ASO and EAP arrangements.

        Public Sector.    The Managed Behavioral Healthcare Public Sector segment ("Public Sector") generally reflects services provided to Medicaid recipients under contracts with state and local governmental agencies. Public Sector contracts encompass either risk-based or ASO arrangements.

Radiology Benefits Management

        The Radiology Benefits Management segment generally reflects the management of the delivery of diagnostic imaging services to ensure that such services are clinically appropriate and cost effective. The Company's radiology benefits management services currently are provided under contracts with managed care companies, health insurers and other health plans for some or all of their commercial, Medicaid and Medicare members. The Company has bid on contracts with state and local governmental agencies for the provision of such services to Medicaid recipients. The Company has won one state Medicaid contract, which was implemented in July 2008. The Company offers its radiology benefits management services through ASO contracts, where the Company provides services such as utilization review and claims administration, but does not assume responsibility for the cost of the imaging services, and through risk-based contracts, where the Company assumes all or a substantial portion of the responsibility for the cost of providing diagnostic imaging services.

7


Table of Contents


MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

March 31, 2009

(Unaudited)

NOTE A—General (Continued)


Specialty Pharmaceutical Management

        The Specialty Pharmaceutical Management segment generally reflects the management of specialty drugs used in the treatment of cancer, multiple sclerosis, hemophilia, infertility, rheumatoid arthritis, chronic forms of hepatitis and other diseases. Specialty pharmaceutical drugs represent high-cost injectible, infused, oral, or inhaled drugs which traditional retail pharmacies often do not supply due to their high cost, sensitive handling, and storage needs. The Company's specialty pharmaceutical management services are provided under contracts with managed care companies, health insurers and other health plans for some or all of their commercial, Medicare and Medicaid members. The Company's specialty pharmaceutical services include (i) contracting and formulary optimization on behalf of health plans and pharmaceutical manufacturers; (ii) distributing specialty pharmaceutical drugs on behalf of health plans; (iii) providing strategic consulting services to health plans and pharmaceutical manufacturers; and (iv) providing oncology benefits management services to health plans.

Corporate and Other

        This segment of the Company is comprised primarily of operational support functions such as sales and marketing and information technology, as well as corporate support functions such as executive, finance, human resources and legal.

Summary of Significant Accounting Policies

Recent Accounting Pronouncements

        In September 2006, the Financial Accounting Standards Board ("FASB") issued Statement of Financial Accounting Standards ("SFAS") No. 157 ("SFAS 157"), which provides guidance for using fair value to measure assets and liabilities. It also responds to investors' requests for expanded information about the extent to which companies measure assets and liabilities at fair value, the information used to measure fair value and the effect of fair value measurements on earnings. SFAS 157 applies whenever other standards require (or permit) assets or liabilities to be measured at fair value, and does not expand the use of fair value in any new circumstances. SFAS 157 is effective for fiscal years beginning after November 15, 2007. In February 2008, the FASB issued FASB Staff Position No. 157-2, Effective Date of FASB Statement No. 157 ("FSP 157-2"), which delays the effective date of SFAS 157 by one year for all non-financial assets and non-financial liabilities, except those that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). On January 1, 2008, the Company adopted SFAS 157 for financial assets and liabilities. The adoption did not have a material impact on the consolidated financial statements. On January 1, 2009, the Company adopted SFAS 157 for non-financial assets and non-financial liabilities. The adoption did not have a material impact on the consolidated financial statements.

        In December 2007, the FASB issued SFAS No. 141(R) "Business Combinations" ("SFAS 141(R)") and SFAS No. 160, "Non-controlling Interests in Consolidated Financial Statements" ("SFAS 160"). SFAS 141(R) requires the acquiring entity in a business combination to record all assets acquired and liabilities assumed at their respective acquisition-date fair values and changes other practices under

8


Table of Contents


MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

March 31, 2009

(Unaudited)

NOTE A—General (Continued)


SFAS 141, some of which could have a material impact on how the Company accounts for future business combinations. SFAS 141(R) also requires additional disclosure of information surrounding a business combination, such that users of the entity's financial statements can fully understand the nature and financial impact of the business combination. SFAS 160 requires entities to report non-controlling (minority) interests in subsidiaries as equity in the consolidated financial statements. The Company adopted SFAS 141(R) and SFAS 160 simultaneously in the Company's year beginning January 1, 2009. Prior to 2009 and in accordance with American Institute of Certified Public Accountants ("AICPA") Statement of Position ("SOP") 90-7, "Financial Reporting by Entities in Reorganization Under the Bankruptcy Code" ("SOP 90-7"), reversals of both valuation allowances and unrecognized tax benefits with respect to years prior to the Company's reorganization were recorded to goodwill. All other reversals of these balances were recorded as reductions to income tax expense. As a result of the implementation of SFAS 141(R), beginning in 2009 all reversals of valuation allowances and unrecognized tax benefits are reflected as reductions to income tax expense, even if related to years prior to the Company's reorganization. The adoption of SFAS 160 did not have a material impact on the consolidated financial statements.

Use of Estimates

        The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates of the Company include, among other things, accounts receivable realization, valuation allowances for deferred tax assets, valuation of goodwill and intangible assets, medical claims payable, other medical liabilities, stock compensation assumptions, tax contingencies and legal liabilities. Actual results could differ from those estimates.

Managed Care Revenue

        Managed care revenue, inclusive of revenue from the Company's risk, EAP and ASO contracts, is recognized over the applicable coverage period on a per member basis for covered members. The Company is paid a per member fee for all enrolled members, and this fee is recorded as revenue in the month in which members are entitled to service. The Company adjusts its revenue for retroactive membership terminations, additions and other changes, when such adjustments are identified, with the exception of retroactivity that can be reasonably estimated. Any fees paid prior to the month of service are recorded as deferred revenue. Managed care revenues approximated $593.3 million and $554.2 million for the three months ended March 31, 2008 and 2009, respectively.

Cost-Plus Contracts

        The Company has certain cost-plus contracts with customers under which the Company recognizes revenue as costs are incurred and as services are performed. Revenues from cost-plus contracts approximated $7.2 million and $7.5 million for the three months ended March 31, 2008 and 2009, respectively.

9


Table of Contents


MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

March 31, 2009

(Unaudited)

NOTE A—General (Continued)

Block Grant Revenues

        The Maricopa Contract is partially funded by federal, state and county block grant money, which represents annual appropriations. The Company recognizes revenue from block grant activity ratably over the period to which the block grant funding applies. Block grant revenues were approximately $30.6 million and $25.5 million for the three months ended March 31, 2008 and 2009, respectively.

Distribution Revenue

        The Company recognizes distribution revenue, which includes the co-payments received from members of the health plans the Company serves, when the specialty pharmaceutical drugs are shipped. At the time of shipment, the earnings process is complete; the obligation of the Company's customer to pay for the specialty pharmaceutical drugs is fixed, and, due to the nature of the product, the member may neither return the specialty pharmaceutical drugs nor receive a refund. Revenues from the distribution of specialty pharmaceutical drugs on behalf of health plans were $50.0 million and $56.6 million for the three months ended March 31, 2008 and 2009, respectively.

Performance-based Revenue

        The Company has the ability to earn performance-based revenue under certain risk and non-risk contracts. Performance-based revenue generally is based on either the ability of the Company to manage care for its clients below specified targets, or on other operating metrics. For each such contract, the Company estimates and records performance-based revenue after considering the relevant contractual terms and the data available for the performance-based revenue calculation. Pro-rata performance-based revenue is recognized on an interim basis pursuant to the rights and obligations of each party upon termination of the contracts. Performance-based revenues were $3.9 million and $1.3 million for the three months ended March 31, 2008 and 2009, respectively.

Significant Customers

        The Maricopa Contract generated net revenues that exceeded, in the aggregate, ten percent of net revenues for the consolidated Company for the three months ended March 31, 2008 and 2009. In addition to the Maricopa Contract, the Company's contract with the State of Tennessee's TennCare program ("TennCare") generated net revenues that exceeded, in the aggregate, ten percent of net revenues for the consolidated Company for the three months ended March 31, 2008. The Company also has a significant concentration of business from contracts with subsidiaries of WellPoint, Inc. ("WellPoint") and with various counties in the State of Pennsylvania (the "Pennsylvania Counties") which are part of the Pennsylvania Medicaid program.

        The Maricopa Contract, which began September 1, 2007 and which extends through June 30, 2010, generated net revenues of $149.5 million and $168.5 million for the three months ended March 31, 2008 and 2009, respectively.

10


Table of Contents


MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

March 31, 2009

(Unaudited)

NOTE A—General (Continued)

        The TennCare program is divided into three regions, and through March 31, 2007 the Company's TennCare contracts encompassed all of the TennCare membership for all three regions. As of April 1, 2007 substantially all of the membership in the Middle Grand Region was re-assigned to managed care companies in accordance with contract awards by TennCare pursuant to its request for proposals for the management of the integrated delivery of behavioral and physical medical care to the region. Substantially all of the membership in the West Grand and East Grand Regions was similarly re-assigned to managed care companies in accordance with contract awards by TennCare effective November 1, 2008 and January 1, 2009, respectively. The Company continues to manage behavioral healthcare services for children enrolled in TennCare Select High, statewide, as well as for certain out-of-state TennCare members pursuant to contracts that extend through June 30, 2009. The Company recorded net revenues of $70.8 million and $12.8 million for the three months ended March 31, 2008 and 2009, respectively, from its TennCare contracts.

        Total net revenues from the Company's contracts with WellPoint were $51.6 million and $44.0 million during the three months ended March 31, 2008 and 2009, respectively, including radiology benefits management revenue of $42.0 million and $40.6 million, respectively.

        In July 2007, WellPoint acquired a radiology benefits management company, and has expressed its intent to in-source all of its radiology benefits management contracts when such contracts expire. The Company had several radiology benefits management contracts with WellPoint including one that converted from an ASO arrangement to a risk arrangement effective July 1, 2007. Such risk contract originally had a three-year term through June 30, 2010, and cannot be terminated early, except for cause, as defined in the agreement. The term of this risk contract has been extended through December 31, 2010. The Company's other radiology benefits management ASO contracts with WellPoint generated $4.6 million of net revenues for the three months ended March 31, 2008, and these ASO contracts terminated at various dates in 2008.

        Net revenues from the Pennsylvania Counties in the aggregate totaled $71.3 million and $74.8 million for the three months ended March 31, 2008 and 2009, respectively.

        Two customers generated greater than ten percent of Commercial net revenues for the three months ended March 31, 2008 and 2009. The first customer has a contract that extends through December 31, 2012 and generated net revenues of $49.6 million and $57.3 million for the three months ended March 31, 2008 and 2009, respectively. The second customer has a contract that extends through June 30, 2009 and generated net revenues of $22.1 million and $21.9 million for the three months ended March 31, 2008 and 2009, respectively. On April 30, 2009, the Company and this customer entered into a new contract with a term expiring June 30, 2014, terminable without cause upon 180 days' notice after the third anniversary of the contract.

        In addition to the Maricopa Contract and TennCare, one other customer generated net revenues greater than ten percent of the net revenues for the Public Sector segment for the three months ended March 31, 2008 and 2009. This customer has a contract that extends through December 31, 2009 and generated net revenues of $37.2 million and $36.0 million, respectively. Pursuant to an RFP process,

11


Table of Contents


MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

March 31, 2009

(Unaudited)

NOTE A—General (Continued)


the customer notified the Company of its intent to award the contract to provide servicing beyond December 31, 2009. The award is subject to the negotiation and execution of a contract between the Company and the customer. The proposed new contract will have a term of 2.5 years beginning on January 1, 2010 with options for the customer to extend the term of the contract for three one year terms.

        In addition to WellPoint, one other customer generated greater than ten percent of the net revenues for the Radiology Benefits Management segment for the three months ended March 31, 2008 and 2009. This customer has a contract that extends through May 31, 2011 and generated net revenues of $24.9 million and $22.6 million for the three months ended March 31, 2008 and 2009, respectively.

        Included in the Company's Specialty Pharmaceutical Management segment are five customers that each exceeded ten percent of the net revenues for this segment for the three months ended March 31, 2008. Four of such customers generated $17.1 million, $13.6 million, $7.5 million, and $7.1 million of net revenues during the three months ended March 31, 2008. The other contract generated net revenues of $7.2 million for the three months ended March 31, 2008, and this contract terminated as of December 31, 2008. For the three months ended March 31, 2009, four customers each exceeded ten percent of the net revenues for this segment. Four of such customers generated $20.2 million, $13.9 million, $9.3 million, and $7.3 million of net revenues during the three months ended March 31, 2009. The previously mentioned contract that terminated as of December 31, 2008 generated net revenues for run-off activity of $6.6 million for the three months ended March 31, 2009.

Fair Value Measurements

        The Company adopted SFAS 157 on January 1, 2008. SFAS 157 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). The standard outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. Under generally accepted accounting practices, certain assets and liabilities must be measured at fair value, and SFAS 157 details the disclosures that are required for items measured at fair value.

        The Company has various financial instruments that must be measured under the new fair value standard including investments, which consist primarily of U.S. Government securities, obligations of government-sponsored enterprises, corporate debt securities and certificates of deposit. The Company currently does not have non-financial assets and non-financial liabilities that are required to be measured at fair value on a recurring basis. Pursuant to SFAS 157, financial assets and liabilities are to be measured using inputs from the three levels of the fair value hierarchy, which are as follows:

        Level 1—Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that we have the ability to access at the measurement date.

        Level 2—Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves, etc.), and

12


Table of Contents


MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

March 31, 2009

(Unaudited)

NOTE A—General (Continued)


inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).

        Level 3—Unobservable inputs that reflect our assumptions about the assumptions that market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available, including the Company's data.

        In accordance with the fair value hierarchy described above, the following table shows the fair value of the Company's financial assets and liabilities that are required to be measured at fair value as of March 31, 2009 (in thousands):

 
  Fair Value Measurements at March 31, 2009  
 
  Level 1   Level 2   Level 3   Total  

Cash and Cash Equivalents(1)

  $   $ 116,409   $   $ 116,409  

Restricted Cash(2)

        100,948         100,948  

Investments:

                         

U.S. Government and agency securities

    685             685  

Obligations of government-sponsored enterprises(3)

        50,570         50,570  

Corporate debt securities

        184,349         184,349  

Certificates of deposit

        26,269         26,269  
                   

  $ 685   $ 478,545   $   $ 479,230  
                   

(1)
Excludes $61.9 million of cash held in bank accounts by the Company.

(2)
Excludes $27.1 million of restricted cash held in bank accounts by the Company.

(3)
Includes investments in notes issued by the Federal Home Loan Mortgage Corporation, the Federal National Mortgage Association and the Federal Home Loan Bank.

Income Taxes

        The Company's effective income tax rate was 41.6 percent and 42.3 percent for the three months ended March 31, 2008 and 2009, respectively. These rates differ from the federal statutory income tax rate primarily due to state income taxes and permanent differences between book and tax income. The Company also accrues interest and penalties related to unrecognized tax benefits in its provision for income taxes.

Stock Compensation

        The Company measures stock compensation under SFAS No. 123 (revised 2004) "Share-Based Payment" ("SFAS 123R"). At December 31, 2008 and March 31, 2009, the Company had equity-based employee incentive plans, which are described more fully in Note 7 in the Company's Annual Report on Form 10-K for the year ended December 31, 2008. Under SFAS 123R, the Company recorded stock compensation expense of $12.0 million and $6.4 million for the three months ended March 31, 2008

13


Table of Contents


MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

March 31, 2009

(Unaudited)

NOTE A—General (Continued)


and 2009, respectively. Stock compensation expense recognized in the condensed consolidated statements of income for the three months ended March 31, 2008 and 2009 has been reduced for estimated forfeitures, estimated at two percent and five percent, respectively.

        The weighted average grant date fair value of all stock options granted during the three months ended March 31, 2009 was $8.69 as estimated using the Black-Scholes-Merton option pricing model, which also assumed an expected volatility of 30.2 percent based on the historical volatility of the Company's stock price.

        SFAS 123R also requires the benefits of tax deductions in excess of recognized stock compensation expense to be reported as a financing cash flow, rather than as an operating cash flow. In the three months ended March 31, 2008 and 2009, approximately $0.1 million and $1.1 million of benefits of such tax deductions related to stock compensation expense were realized and as such were reported as financing cash flows, respectively.

        Summarized information related to the Company's stock options for the three months ended March 31, 2009 is as follows:

 
  Options   Weighted Average
Exercise Price
 

Outstanding, beginning of period

    4,668,490   $ 39.82  

Granted

    1,095,769     33.08  

Cancelled

    (167,007 )   41.53  

Exercised

    (29,435 )   30.99  
           

Outstanding, end of period

    5,567,817     38.49  
           

Vested and expected to vest at end of period

    5,386,817     38.53  
           

Exercisable, end of period

    2,916,350   $ 39.09  
           

        All of the Company's options granted during the three months ended March 31, 2009 vest ratably on each anniversary date over the three years subsequent to grant, and all have a ten year life.

        Summarized information related to the Company's nonvested restricted stock awards for the three months ended March 31, 2009 is as follows:

 
  Shares   Weighted
Average
Grant Date
Fair Value
 

Outstanding, beginning of period

    321,935   $ 42.92  

Awarded

    869     33.51  

Vested

    (25,717 )   35.83  

Forfeited

    (481 )   34.57  
           

Outstanding, ending of period

    296,606   $ 43.52  
           

14


Table of Contents


MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

March 31, 2009

(Unaudited)

NOTE A—General (Continued)

        Summarized information related to the Company's nonvested restricted stock units for the three months ended March 31, 2009 is as follows:

 
  Shares   Weighted
Average
Grant Date
Fair Value
 

Outstanding, beginning of period

    176,112   $ 38.72  

Awarded

    121,065     32.91  

Vested

    (76,471 )   32.60  

Forfeited

    (13,871 )   39.78  
           

Outstanding, ending of period

    206,835   $ 37.51  
           

        Restricted stock awards and restricted stock units granted during the three months ended March 31, 2009 vest ratably on each anniversary date over the three years subsequent to grant.

Long Term Debt and Capital Lease Obligations

        On April 30, 2008, the Company entered into a credit facility with Deutsche Bank AG and Citigroup Global Markets Inc. that provided for a $100.0 million Revolving Loan Commitment for the issuance of letters of credit for the account of the Company with a sublimit of up to $30.0 million for revolving loans (the "2008 Credit Facility"). On April 30, 2008, the Company's credit agreement with Deutsche Bank AG dated January 5, 2004, as amended (the "Credit Agreement") was terminated. Borrowings under the 2008 Credit Facility, if any, matured on April 29, 2009. The 2008 Credit Facility was guaranteed by substantially all of the subsidiaries of the Company and was secured by substantially all of the assets of the Company and the subsidiary guarantors.

        Under the 2008 Credit Facility, the annual interest rate on Revolving Loan borrowings bear interest at a rate equal to the sum of (i) a borrowing margin of 1.00 percent plus (ii) (A) in the case of U.S. dollar denominated loans, the higher of the prime rate or one-half of one percent in excess of the overnight "federal funds" rate, or (B) in the case of Eurodollar denominated loans, an interest rate which is a function of the Eurodollar rate for the selected interest period. The Company has the option to borrow in U.S. dollar denominated loans or Eurodollar denominated loans at its discretion. Letters of Credit issued under the Revolving Loan Commitment bear interest at the rate of 1.125 percent. The commitment commission on the 2008 Credit Facility was 0.375 percent of the unused Revolving Loan Commitment.

        At March 31, 2009, the annual interest rate on the Company's capital lease obligation due through 2011 was 6.87 percent. There were no Revolving Loan borrowings at March 31, 2009.

        On April 29, 2009, the Company entered into an amendment to the 2008 Credit Facility with Deutsche Bank AG, Citibank, N.A., and Bank of America, N.A. that provides for an $80.0 million Revolving Loan Commitment for the issuance of letters of credit for the account of the Company with a sublimit of up to $30.0 million for revolving loans (the "2009 Credit Facility"). Borrowings under the 2009 Credit Facility will mature on April 28, 2010. The 2009 Credit Facility is guaranteed by

15


Table of Contents


MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

March 31, 2009

(Unaudited)

NOTE A—General (Continued)


substantially all of the subsidiaries of the Company and is secured by substantially all of the assets of the Company and the subsidiary guarantors.

        Under the 2009 Credit Facility, the annual interest rate on Revolving Loan borrowings bear interest at a rate equal to (i) in the case of U.S. dollar denominated loans, the sum of a borrowing margin of 2.25 percent plus the higher of the prime rate or one-half of one percent in excess of the overnight "federal funds" rate, or (ii) in the case of Eurodollar denominated loans, the sum of a borrowing margin of 3.25 percent plus the Eurodollar rate for the selected interest period. The Company has the option to borrow in U.S. dollar denominated loans or Eurodollar denominated loans at its discretion. Letters of Credit issued under the Revolving Loan Commitment bear interest at the rate of 3.375 percent. The commitment commission on the 2009 Credit Facility is 0.625 percent of the unused Revolving Loan Commitment.

NOTE B—Net Income per Common Share

        The following tables reconcile income (numerator) and shares (denominator) used in the computations of net income per common share (in thousands, except per share data):

 
  Three Months
Ended
March 31,
 
 
  2008   2009  

Numerator:

             

Net income

  $ 17,244   $ 13,560  
           

Denominator:

             

Weighted average number of common shares outstanding—basic

    39,736     36,208  
 

Common stock equivalents—stock options

    394     86  
 

Common stock equivalents—warrants

    167     87  
 

Common stock equivalents—restricted stock

    7     5  
 

Common stock equivalents—restricted stock units

    36      
 

Common stock equivalents—employee stock purchase plan

         
           

Weighted average number of common shares outstanding—diluted

    40,340     36,386  
           

Net income per common share—basic

  $ 0.43   $ 0.37  
           

Net income per common share—diluted

  $ 0.43   $ 0.37  
           

        The weighted average number of common shares outstanding for the three months ended March 31, 2008 and 2009 was calculated using outstanding shares of the Company's Ordinary Common Stock. Common stock equivalents included in the calculation of diluted weighted average common shares outstanding for the three months ended March 31, 2008 and 2009 represent stock options to purchase shares of the Company's Ordinary Common Stock, restricted stock awards and restricted stock units, stock to be purchased under the Employee Stock Purchase Plan and shares of Ordinary Common Stock related to certain warrants issued on January 5, 2004.

16


Table of Contents


MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

March 31, 2009

(Unaudited)

NOTE B—Net Income per Common Share (Continued)

        For the three months ended March 31, 2009, the Company had additional potential dilutive securities outstanding representing 4.3 million options, 0.3 million restricted stock awards and 0.3 million restricted stock units that were not included in the computation of dilutive securities because they were anti-dilutive for the period. Had these shares not been anti-dilutive, all of these shares would not have been included in the net income per common share calculation as the Company uses the treasury stock method of calculating diluted shares.

NOTE C—Business Segment Information

        The accounting policies of the Company's segments are the same as those described in Note A—"General." The Company evaluates performance of its segments based on profit or loss from continuing operations before stock compensation expense, depreciation and amortization, interest expense, interest income, gain on sale of assets, special charges or benefits, and income taxes ("Segment Profit"). Management uses Segment Profit information for internal reporting and control purposes and considers it important in making decisions regarding the allocation of capital and other resources, risk assessment and employee compensation, among other matters. Intersegment sales and transfers are not significant.

        The following tables summarize, for the periods indicated, operating results by business segment (in thousands):

 
  Commercial   Public
Sector
  Radiology
Benefits
Management
  Specialty
Pharmaceutical
Management
  Corporate
and
Other
  Consolidated  

Three Months Ended March 31, 2008

                                     
 

Net revenue

  $ 159,603   $ 358,238   $ 75,499   $ 56,950   $   $ 650,290  
 

Cost of care

    (81,573 )   (323,174 )   (49,327 )           (454,074 )
 

Cost of goods sold

                (46,824 )       (46,824 )
 

Direct service costs

    (37,425 )   (16,623 )   (13,100 )   (5,920 )       (73,068 )
 

Other operating expenses

                    (36,680 )   (36,680 )
 

Stock compensation expense(1)

    423     174     505     2,104     8,812     12,018  
                           
 

Segment profit (loss)

  $ 41,028   $ 18,615   $ 13,577   $ 6,310   $ (27,868 ) $ 51,662  
                           

 

 
  Commercial   Public
Sector
  Radiology
Benefits
Management
  Specialty
Pharmaceutical
Management
  Corporate
and
Other
  Consolidated  

Three Months Ended March 31, 2009

                                     
 

Net revenue

  $ 158,753   $ 321,860   $ 73,559   $ 65,343   $   $ 619,515  
 

Cost of care

    (89,786 )   (292,146 )   (49,786 )           (431,718 )
 

Cost of goods sold

                (52,072 )       (52,072 )
 

Direct service costs

    (38,525 )   (17,296 )   (13,038 )   (6,394 )       (75,253 )
 

Other operating expenses

                    (27,811 )   (27,811 )
 

Stock compensation expense(1)

    332     235     370     2,082     3,413     6,432  
                           
 

Segment profit (loss)

  $ 30,774   $ 12,653   $ 11,105   $ 8,959   $ (24,398 ) $ 39,093  
                           

(1)
Stock compensation expense is included in direct service costs and other operating expenses, however this amount is excluded from the computation of Segment Profit since it is managed on a consolidated basis.

17


Table of Contents


MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

March 31, 2009

(Unaudited)

NOTE C—Business Segment Information (Continued)

        The following table reconciles Segment Profit to consolidated income from continuing operations before income taxes (in thousands):

 
  Three Months Ended
March 31,
 
 
  2008   2009  

Segment profit

  $ 51,662   $ 39,093  

Stock compensation expense

    (12,018 )   (6,432 )

Depreciation and amortization

    (14,374 )   (11,043 )

Interest expense

    (1,215 )   (427 )

Interest income

    5,493     2,311  
           
 

Income from continuing operations before income taxes

  $ 29,548   $ 23,502  
           

NOTE D—Commitments and Contingencies

Legal

        The management and administration of the delivery of specialty managed healthcare entails significant risks of liability. From time to time, the Company is subject to various actions and claims arising from the acts or omissions of its employees, network providers or other parties. In the normal course of business, the Company receives reports relating to deaths and other serious incidents involving patients whose care is being managed by the Company. Such incidents occasionally give rise to malpractice, professional negligence and other related actions and claims against the Company or its network providers. Many of these actions and claims received by the Company seek substantial damages and therefore require the Company to incur significant fees and costs related to their defense. The Company is also subject to or party to certain class actions, litigation and claims relating to its operations and business practices. In the opinion of management, the Company has recorded reserves that are adequate to cover litigation, claims or assessments that have been or may be asserted against the Company, and for which the outcome is probable and reasonably estimable. Management believes that the resolution of such litigation and claims will not have a material adverse effect on the Company's financial condition or results of operations; however, there can be no assurance in this regard.

Stock Repurchase

        On July 30, 2008 the Company's board of directors approved a stock repurchase plan which authorizes the Company to purchase up to $200 million of its outstanding common stock through January 31, 2010. Stock repurchases under the program may be executed through open market repurchases, privately negotiated transactions, accelerated share repurchases or other means. The board of directors authorized management to execute stock repurchase transactions from time to time and in such amounts and via such methods as management deems appropriate. The stock repurchase program may be limited or terminated at any time without prior notice. Pursuant to this program, the Company made open market purchases of 1,799,933 shares of the Company's common stock at an average share price of $34.32 per share for an aggregate cost of $61.8 million (excluding broker commissions) during the three months ended March 31, 2009. As of March 31, 2009, the amount of stock repurchases that remained under the program was $2.2 million and such remaining repurchases were made during the period subsequent to March 31, 2009, completing the repurchase program as of April 7, 2009.

18


Table of Contents

Item 2.    Management's Discussion and Analysis of Financial Condition and Results of Operations.

        The following discussion and analysis of the financial condition and results of operations of Magellan Health Services, Inc. ("Magellan"), and its majority-owned subsidiaries and all variable interest entities ("VIEs") for which Magellan is the primary beneficiary (together with Magellan, the "Company") should be read together with the Condensed Consolidated Financial Statements and the notes to the Condensed Consolidated Financial Statements included elsewhere in this Quarterly Report on Form 10-Q and the Company's Annual Report on Form 10-K for the year ended December 31, 2008, which was filed with the Securities and Exchange Commission ("SEC") on February 27, 2009.

Forward-Looking Statements

        This Form 10-Q includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Although the Company believes that its plans, intentions and expectations as reflected in such forward-looking statements are reasonable, it can give no assurance that such plans, intentions or expectations will be achieved. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-looking statements include:

19


Table of Contents

        Further discussion of factors currently known to management that could cause actual results to differ materially from those in forward-looking statements is set forth under the heading "Risk Factors" in Item 1A of Magellan's Annual Report on Form 10-K for the year ended December 31, 2008. When used in this Quarterly Report on Form 10-Q, the words "estimate," "anticipate," "expect," "believe," "should," and similar expressions are intended to be forward-looking statements. Magellan undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results over time.

Business Overview

        The Company is engaged in the specialty managed healthcare business. Through 2005, the Company predominantly operated in the managed behavioral healthcare business. During 2006, the Company expanded into radiology benefits management and specialty pharmaceutical management as a result of certain acquisitions. The Company provides services to health plans, insurance companies, corporations, labor unions and various governmental agencies. The Company's business is divided into the following five segments, based on the services it provides and/or the customers that it serves, as described below.

Managed Behavioral Healthcare

        Two of the Company's segments are in the managed behavioral healthcare business. This line of business generally reflects the Company's coordination and management of the delivery of behavioral healthcare treatment services that are provided through its contracted network of third-party treatment providers, which includes psychiatrists, psychologists, other behavioral health professionals, psychiatric hospitals, general medical facilities with psychiatric beds, residential treatment centers and other treatment facilities. The treatment services provided through the Company's provider network include outpatient programs (such as counseling or therapy), intermediate care programs (such as intensive outpatient programs and partial hospitalization services), inpatient treatment and crisis intervention services. The Company generally does not directly provide, or own any provider of, treatment services except as relates to the Company's contract to provide managed behavioral healthcare services to Medicaid recipients and other beneficiaries of the Maricopa County Regional Behavioral Health Authority (the "Maricopa Contract"). Under the Maricopa Contract, effective August 31, 2007 the Company was required to assume the operations of twenty-four behavioral health direct care facilities for a transitional period and to divest itself of these facilities over a two year period. During March 2009, the Company began the operation of two additional behavioral health direct care facilities. At various dates in 2008 and 2009, the Company entered into agreements with three separate Provider

20


Table of Contents


Network Organizations ("PNOs") to transition 20 of the 26 behavioral health direct care facilities to the PNOs over various dates. Fourteen of such direct care facilities have been transitioned through April 2009 and the Company expects to divest itself of the remainder of these facilities before August 31, 2009.

        The Company provides its management services primarily through: (i) risk-based products, where the Company assumes all or a substantial portion of the responsibility for the cost of providing treatment services in exchange for a fixed per member per month fee, (ii) administrative services only ("ASO") products, where the Company provides services such as utilization review, claims administration and/or provider network management, but does not assume responsibility for the cost of the treatment services, and (iii) employee assistance programs ("EAPs") where the Company provides short-term outpatient behavioral counseling services.

        The managed behavioral healthcare business is managed based on the services provided and/or the customers served, through the following two segments:

        Commercial.    The Managed Behavioral Healthcare Commercial segment ("Commercial") generally reflects managed behavioral healthcare services and EAP services provided under contracts with managed care companies, health insurers and other health plans for some or all of their commercial, Medicaid and Medicare members, as well as with employers, including corporations and governmental agencies, and labor unions. Commercial's contracts encompass risk-based, ASO and EAP arrangements. As of March 31, 2009, Commercial's covered lives were 4.0 million, 13.7 million and 20.8 million for risk-based, EAP and ASO products, respectively. For the three months ended March 31, 2009, Commercial's revenue was $100.9 million, $26.2 million and $31.7 million for risk-based, EAP and ASO products, respectively.

        Public Sector.    The Managed Behavioral Healthcare Public Sector segment ("Public Sector") generally reflects services provided to Medicaid recipients under contracts with state and local governmental agencies. Public Sector contracts encompass either risk-based or ASO arrangements. As of March 31, 2009, Public Sector's covered lives were 1.4 million and 0.3 million for risk-based and ASO products, respectively. For the three months ended March 31, 2009, Public Sector's revenue was $320.3 million and $1.6 million for risk-based and ASO products, respectively.

Radiology Benefits Management

        The Radiology Benefits Management segment generally reflects the management of the delivery of diagnostic imaging services to ensure that such services are clinically appropriate and cost effective. The Company's radiology benefits management services currently are provided under contracts with managed care companies, health insurers and other health plans for some or all of their commercial, Medicaid and Medicare members. The Company has bid on contracts with state and local governmental agencies for the provision of such services to Medicaid recipients. The Company has won one state Medicaid contract, which was implemented in July 2008. The Company offers its radiology benefits management services through ASO contracts, where the Company provides services such as utilization review and claims administration, but does not assume responsibility for the cost of the imaging services, and through risk-based contracts, where the Company assumes all or a substantial portion of the responsibility for the cost of providing diagnostic imaging services. As of March 31, 2009, covered lives for Radiology Benefits Management were 2.4 million and 14.9 million for risk-based and ASO products, respectively. For the three months ended March 31, 2009, revenue for Radiology Benefits Management was $60.0 million and $13.6 million for risk-based and ASO products, respectively.

21


Table of Contents


Specialty Pharmaceutical Management

        The Specialty Pharmaceutical Management segment generally reflects the management of specialty drugs used in the treatment of cancer, multiple sclerosis, hemophilia, infertility, rheumatoid arthritis, chronic forms of hepatitis and other diseases. Specialty pharmaceutical drugs represent high-cost injectible, infused, oral, or inhaled drugs which traditional retail pharmacies often do not supply due to their high cost, sensitive handling, and storage needs. The Company's specialty pharmaceutical management services are provided under contracts with managed care companies, health insurers and other health plans for some or all of their commercial, Medicare and Medicaid members. The Company's specialty pharmaceutical services include (i) contracting and formulary optimization on behalf of health plans and pharmaceutical manufacturers; (ii) distributing specialty pharmaceutical drugs on behalf of health plans; (iii) providing strategic consulting services to health plans and pharmaceutical manufacturers; and (iv) providing oncology benefits management services to health plans. The Company's Specialty Pharmaceutical Management segment had contracts with 40 health plans as of March 31, 2009.

Corporate and Other

        This segment of the Company is comprised primarily of operational support functions such as sales and marketing and information technology, as well as corporate support functions such as executive, finance, human resources and legal.

Significant Customers

        The Maricopa Contract generated net revenues that exceeded, in the aggregate, ten percent of net revenues for the consolidated Company for the three months ended March 31, 2008 and 2009. In addition to the Maricopa Contract, the Company's contract with the State of Tennessee's TennCare program ("TennCare") generated net revenues that exceeded, in the aggregate, ten percent of net revenues for the consolidated Company for the three months ended March 31, 2008. The Company also has a significant concentration of business from contracts with subsidiaries of WellPoint, Inc. ("WellPoint") and with various counties in the State of Pennsylvania (the "Pennsylvania Counties") which are part of the Pennsylvania Medicaid program.

        The Maricopa Contract, which began September 1, 2007 and which extends through June 30, 2010, generated net revenues of $149.5 million and $168.5 million for the three months ended March 31, 2008 and 2009, respectively.

        The TennCare program is divided into three regions, and through March 31, 2007 the Company's TennCare contracts encompassed all of the TennCare membership for all three regions. As of April 1, 2007 substantially all of the membership in the Middle Grand Region was re-assigned to managed care companies in accordance with contract awards by TennCare pursuant to its request for proposals for the management of the integrated delivery of behavioral and physical medical care to the region. Substantially all of the membership in the West Grand and East Grand Regions was similarly re-assigned to managed care companies in accordance with contract awards by TennCare effective November 1, 2008 and January 1, 2009, respectively. The Company continues to manage behavioral healthcare services for children enrolled in TennCare Select High, statewide, as well as for certain out-of-state TennCare members pursuant to contracts that extend through June 30, 2009. The Company recorded net revenues of $70.8 million and $12.8 million for the three months ended March 31, 2008 and 2009, respectively, from its TennCare contracts.

22


Table of Contents

        Total net revenues from the Company's contracts with WellPoint were $51.6 million and $44.0 million during the three months ended March 31, 2008 and 2009, respectively, including radiology benefits management revenue of $42.0 million and $40.6 million, respectively.

        In July 2007, WellPoint acquired a radiology benefits management company, and has expressed its intent to in-source all of its radiology benefits management contracts when such contracts expire. The Company had several radiology benefits management contracts with WellPoint including one that converted from an ASO arrangement to a risk arrangement effective July 1, 2007. Such risk contract originally had a three-year term through June 30, 2010, and cannot be terminated early, except for cause, as defined in the agreement. The term of this risk contract has been extended through December 31, 2010. The Company's other radiology benefits management ASO contracts with WellPoint generated $4.6 million of net revenues for the three months ended March 31, 2008, and these ASO contracts terminated at various dates in 2008.

        Net revenues from the Pennsylvania Counties in the aggregate totaled $71.3 million and $74.8 million for the three months ended March 31, 2008 and 2009, respectively.

        Two customers generated greater than ten percent of Commercial net revenues for the three months ended March 31, 2008 and 2009. The first customer has a contract that extends through December 31, 2012 and generated net revenues of $49.6 million and $57.3 million for the three months ended March 31, 2008 and 2009, respectively. The second customer has a contract that extends through June 30, 2009 and generated net revenues of $22.1 million and $21.9 million for the three months ended March 31, 2008 and 2009, respectively. On April 30, 2009, the Company and this customer entered into a new contract with a term expiring June 30, 2014, terminable without cause upon 180 days' notice after the third anniversary of the contract.

        In addition to the Maricopa Contract and TennCare, one other customer generated net revenues greater than ten percent of the net revenues for the Public Sector segment for the three months ended March 31, 2008 and 2009. This customer has a contract that extends through December 31, 2009 and generated net revenues of $37.2 million and $36.0 million, respectively. Pursuant to an RFP process, the customer notified the Company of its intent to award the contract to provide servicing beyond December 31, 2009. The award is subject to the negotiation and execution of a contract between the Company and the customer. The proposed new contract will have a term of 2.5 years beginning on January 1, 2010 with options for the customer to extend the term of the contract for three one year terms.

        In addition to WellPoint, one other customer generated greater than ten percent of the net revenues for the Radiology Benefits Management segment for the three months ended March 31, 2008 and 2009. This customer has a contract that extends through May 31, 2011 and generated net revenues of $24.9 million and $22.6 million for the three months ended March 31, 2008 and 2009, respectively.

        Included in the Company's Specialty Pharmaceutical Management segment are five customers that each exceeded ten percent of the net revenues for this segment for the three months ended March 31, 2008. Four of such customers generated $17.1 million, $13.6 million, $7.5 million, and $7.1 million of net revenues during the three months ended March 31, 2008. The other contract generated net revenues of $7.2 million for the three months ended March 31, 2008, and this contract terminated as of December 31, 2008. For the three months ended March 31, 2009, four customers each exceeded ten percent of the net revenues for this segment. Four of such customers generated $20.2 million, $13.9 million, $9.3 million, and $7.3 million of net revenues during the three months ended March 31, 2009. The previously mentioned contract that terminated as of December 31, 2008 generated net revenues for run-off activity of $6.6 million for the three months ended March 31, 2009.

23


Table of Contents

Off-Balance Sheet Arrangements

        The Company does not maintain any off-balance sheet arrangements that have, or are reasonably likely to have, a current or future effect on the Company's finances that is material to investors.

Critical Accounting Policies and Estimates

        The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Except as noted below, the Company's critical accounting policies are summarized in the Company's Annual Report on Form 10-K, filed with the SEC on February 27, 2009.

Income Taxes

        The Company's effective income tax rate was 41.6 percent and 42.3 percent for the three months ended March 31, 2008 and 2009, respectively. These rates differ from the federal statutory income tax rate primarily due to state income taxes and permanent differences between book and tax income. The Company also accrues interest and penalties related to unrecognized tax benefits in its provision for income taxes.

        The Company files a consolidated federal income tax return for the Company and its eighty-percent or more owned subsidiaries, and the Company and its subsidiaries file income tax returns in various states and local jurisdictions. With few exceptions, the Company is no longer subject to state or local income tax examinations by tax authorities for years ended prior to December 31, 2005. The statute of limitations regarding the assessment of federal and most state and local income taxes for the year ended December 31, 2005 will expire during 2009.

        Prior to 2009 and in accordance with American Institute of Certified Public Accountants ("AICPA") Statement of Position ("SOP") 90-7, "Financial Reporting by Entities in Reorganization Under the Bankruptcy Code" ("SOP 90-7"), reversals of both valuation allowances and unrecognized tax benefits with respect to years prior to the Company's reorganization were recorded to goodwill. All other reversals of these balances were recorded as reductions to income tax expense. As a result of implementation of SFAS 141(R), beginning in 2009 all reversals of valuation allowances and unrecognized tax benefits will be reflected as reductions to income tax expense, even if related to years prior to the Company's reorganization.

24


Table of Contents

Results of Operations

        The Company evaluates performance of its segments based on profit or loss from continuing operations before stock compensation expense, depreciation and amortization, interest expense, interest income, gain on sale of assets, special charges or benefits, and income taxes ("Segment Profit"). Management uses Segment Profit information for internal reporting and control purposes and considers it important in making decisions regarding the allocation of capital and other resources, risk assessment and employee compensation, among other matters. Intersegment sales and transfers are not significant. The Company's segments are defined above.

        The following tables summarize, for the periods indicated, operating results by business segment (in thousands):

 
  Commercial   Public
Sector
  Radiology
Benefits
Management
  Specialty
Pharmaceutical
Management
  Corporate
and
Other
  Consolidated  

Three Months Ended March 31, 2008

                                     
 

Net revenue

  $ 159,603   $ 358,238   $ 75,499   $ 56,950   $   $ 650,290  
 

Cost of care

    (81,573 )   (323,174 )   (49,327 )           (454,074 )
 

Cost of goods sold

                (46,824 )       (46,824 )
 

Direct service costs

    (37,425 )   (16,623 )   (13,100 )   (5,920 )       (73,068 )
 

Other operating expenses

                    (36,680 )   (36,680 )
 

Stock compensation expense(1)

    423     174     505     2,104     8,812     12,018  
                           
 

Segment profit (loss)

  $ 41,028   $ 18,615   $ 13,577   $ 6,310   $ (27,868 ) $ 51,662  
                           

 

 
  Commercial   Public
Sector
  Radiology
Benefits
Management
  Specialty
Pharmaceutical
Management
  Corporate
and
Other
  Consolidated  

Three Months Ended March 31, 2009

                                     
 

Net revenue

  $ 158,753   $ 321,860   $ 73,559   $ 65,343   $   $ 619,515  
 

Cost of care

    (89,786 )   (292,146 )   (49,786 )           (431,718 )
 

Cost of goods sold

                (52,072 )       (52,072 )
 

Direct service costs

    (38,525 )   (17,296 )   (13,038 )   (6,394 )       (75,253 )
 

Other operating expenses

                    (27,811 )   (27,811 )
 

Stock compensation expense(1)

    332     235     370     2,082     3,413     6,432  
                           
 

Segment profit (loss)

  $ 30,774   $ 12,653   $ 11,105   $ 8,959   $ (24,398 ) $ 39,093  
                           

(1)
Stock compensation expense is included in direct service costs and other operating expenses, however this amount is excluded from the computation of Segment Profit since it is managed on a consolidated basis.
 
  Three Months Ended
March 31,
 
 
  2008   2009  

Segment profit

  $ 51,662   $ 39,093  

Stock compensation expense

    (12,018 )   (6,432 )

Depreciation and amortization

    (14,374 )   (11,043 )

Interest expense

    (1,215 )   (427 )

Interest income

    5,493     2,311  
           
 

Income from continuing operations before income taxes

  $ 29,548   $ 23,502  
           

25


Table of Contents

Quarter ended March 31, 2009 ("Current Year Quarter"), compared to the quarter ended March 31, 2008 ("Prior Year Quarter")

Commercial

Net Revenue

        Net revenue related to Commercial decreased by 0.5 percent or $0.9 million from the Prior Year Quarter to the Current Year Quarter. The decrease in revenue is mainly due to terminated contracts of $9.5 million and favorable retroactive rate and membership adjustments of $3.9 million recorded in the Prior Year Quarter, which decreases were partially offset by increased membership from existing customers of $7.3 million, favorable retroactive membership and rate adjustments of $0.8 million recorded in the Current Year Quarter, revenue from new contracts implemented after (or during) the Prior Year Quarter of $0.8 million, favorable rate changes of $0.6 million, and other net favorable variances of $3.0 million.

Cost of Care

        Cost of care increased by 10.1 percent or $8.2 million from the Prior Year Quarter to the Current Year Quarter. The increase in cost of care is primarily due to increased membership from existing customers of $4.9 million, unfavorable medical claims development for the Prior Year Quarter which was recorded after the Prior Year Quarter of $1.5 million, unfavorable prior period medical claims development recorded in the Current Year Quarter of $0.4 million, and care trends and other net variances of $13.2 million, which increases were partially offset by terminated contracts of $6.2 million and unfavorable prior period medical claims development recorded in the Prior Year Quarter of $5.6 million. Cost of care increased as a percentage of risk revenue (excluding EAP business) from 73.8 percent in the Prior Year Quarter to 81.4 percent in the Current Year Quarter, mainly due to unfavorable care trends, out of period care development, and changes in business mix.

Direct Service Costs

        Direct service costs increased by 2.9 percent or $1.1 million from the Prior Year Quarter to the Current Year Quarter. The increase in direct service costs is mainly attributable to cost incurred to claims processing costs. Direct service costs increased as a percentage of revenue from 23.4 percent in the Prior Year Quarter to 24.3 percent in the Current Year Quarter. The increase in the percentage of direct service costs in relation to revenue is mainly due to changes in business mix.

Public Sector

Net Revenue

        Net revenue related to Public Sector decreased by 10.2 percent or $36.4 million from the Prior Year Quarter to the Current Year Quarter. This decrease is primarily due to the net impact of terminated contracts offset by increased membership from existing customers of $39.2 million, favorable retroactive rate changes recorded in the Prior Year Quarter of $3.6 million, unfavorable retroactive rate and membership changes recorded in the Current Year Quarter of $2.1 million, and other net unfavorable variances of $0.2 million, which decreases was partially offset by net favorable rate and contract funding changes of $8.7 million.

Cost of Care

        Cost of care decreased by 9.6 percent or $31.0 million from the Prior Year Quarter to the Current Year Quarter. This decrease is primarily due to care associated with terminated contracts offset by increased membership from existing customers of $32.4 million, favorable medical claims development for the Prior Year Quarter which was recorded after the Prior Year Quarter of $5.5 million, care

26


Table of Contents


associated with retroactive rate changes for contracts with minimum care requirements recorded in the Prior Year Quarter of $3.1 million, and unfavorable prior period medical claims development recorded in the Prior Year Quarter of $1.2 million, which decreases were partially offset by unfavorable prior period medical claims development recorded in the Current Year Quarter of $3.1 million, care associated with rate changes for contracts with minimum cost of care requirements of $3.9 million, and care trends and other net unfavorable variances of $4.2 million. Cost of care increased as a percentage of risk revenue from 90.5 percent in the Prior Year Quarter to 91.2 percent in the Current Year Quarter mainly due to business mix and net unfavorable care development.

Direct Service Costs

        Direct service costs increased by 4.0 percent or $0.7 million from the Prior Year Quarter to the Current Year Quarter. The increase in direct service costs is primarily due to increased costs associated with the Maricopa Contract. Direct service costs increased as a percentage of revenue from 4.6 percent for the Prior Year Quarter, partially offset by costs from terminated contracts to 5.4 percent in the Current Year Quarter mainly due to business mix.

Radiology Benefits Management

Net Revenue

        Net revenue related to Radiology Benefits Management decreased by 2.6 percent or $1.9 million from the Prior Year Quarter to the Current Year Quarter. This decrease is primarily due to decreased membership from existing customers of $5.8 million, terminated contracts of $3.2 million, and other net decreases of $1.0 million, which decreases were partially offset by favorable rate changes of $8.1 million (including $1.4 million of retroactive rate changes recorded in the Current Year Quarter).

Cost of Care

        Cost of care increased by 0.9 percent or $0.5 million from the Prior Year Quarter to the Current Year Quarter. This increase is primarily attributed to favorable prior period medical claims development of $1.1 million recorded in the Prior Year Quarter and care trends and other net variances of $7.3 million, which increases were partially offset by decreased membership from existing customers of $4.9 million, favorable medical claims development for the Prior Year Quarter which was recorded after the Prior Year Quarter of $2.0 million, and favorable prior period medical claims development recorded in the Current Year Quarter of $1.0 million. Cost of care increased as a percentage of risk revenue from 82.6 percent in the Prior Year Quarter to 83.0 percent in the Current Year Quarter mainly due to care trends.

Direct Service Costs

        Direct service costs decreased by 0.5 percent or $0.1 million from the Prior Year Quarter to the Current Year Quarter. As a percentage of revenue, direct service costs increased from 17.4 percent in the Prior Year Quarter to 17.7 percent in the Current Year Quarter, mainly due to business mix.

Specialty Pharmaceutical Management

Net Revenue

        Net revenue related to Specialty Pharmaceutical Management increased by 14.7 percent or $8.4 million from the Prior Year Quarter to the Current Year Quarter. This increase is primarily due to increased distribution activity from new and existing customers of $9.4 million, and increased consulting and rebate revenue of $1.6 million which increases were partially offset by terminated distribution contracts of $2.6 million.

27


Table of Contents

Cost of Goods Sold

        Cost of goods sold increased by 11.2 percent or $5.2 million from the Prior Year Quarter to the Current Year Quarter. This increase is primarily due to increased distribution activity from new and existing customers of $8.6 million, which increase was partially offset by terminated contracts of $2.4 million and other net favorable variances of $1.0 million. As a percentage of the portion of net revenue that relates to distribution activity, cost of goods sold decreased from 93.6 percent in the Prior Year Quarter to 91.9 percent in the Current Year Quarter, mainly due to business mix.

Direct Service Costs

        Direct service costs increased by 8.0 percent or $0.5 million from the Prior Year Quarter to the Current Year Quarter. This increase is primarily due to expenses required to support the aforementioned increases to revenue. As a percentage of revenue, direct service costs decreased from 10.4 percent in the Prior Year Quarter to 9.8 percent in the Current Year Quarter.

Corporate and Other

Other Operating Expenses

        Other operating expenses related to the Corporate and Other Segment decreased by 24.2 percent or $8.9 million from the Prior Year Quarter to the Current Year Quarter. The decrease results primarily from prior year expenses incurred pursuant to the former Chief Executive Officer's employment agreement in relation to his service to the Company ending of $10.1 million (including $5.4 million of stock compensation expense related to the acceleration of vesting for certain equity awards), which decrease was partially offset by other net unfavorable variances of $1.2 million. As a percentage of total net revenue, other operating expenses decreased from 5.6 percent for the Prior Year Quarter to 4.5 percent for the Current Year Quarter, primarily due to prior year expenses incurred pursuant to the former Chief Executive Officer's employment agreement.

Depreciation and Amortization

        Depreciation and amortization expense decreased by 23.2 percent or $3.3 million from the Prior Year Quarter to the Current Year Quarter, primarily due to assets that became fully depreciated as of December 31, 2008.

Interest Expense

        Interest expense decreased by 64.9 percent or $0.8 million from the Prior Year Quarter to the Current Year Quarter, mainly due to reductions in outstanding debt balances as a result of scheduled payments and lower interest rates in the Current Year Quarter.

Interest Income

        Interest income decreased by $3.2 million from the Prior Year Quarter to the Current Year Quarter, mainly due to lower yields.

Income Taxes

        The Company's effective income tax rate was 41.6 percent in the Prior Year Quarter and 42.3 percent in the Current Year Quarter. The Prior Year Quarter and Current Year Quarter effective income tax rates differ from the federal statutory income tax rate primarily due to state income taxes and permanent differences between book and tax income.

28


Table of Contents

Outlook—Results of Operations

        The Company's Segment Profit and net income are subject to significant fluctuations from period to period. These fluctuations may result from a variety of factors such as those set forth under Item 2—"Forward-Looking Statements" as well as a variety of other factors including: (i) changes in utilization levels by enrolled members of the Company's risk-based contracts, including seasonal utilization patterns; (ii) contractual adjustments and settlements; (iii) retrospective membership adjustments; (iv) timing of implementation of new contracts, enrollment changes and contract terminations; (v) pricing adjustments upon contract renewals (and price competition in general); and (vi) changes in estimates regarding medical costs and incurred but not yet reported medical claims.

        Care Trends.    The Company expects that the care trend factors for 2009 for Commercial will be 7 to 9 percent, Public Sector will be 3 to 5 percent, and Radiology Benefits Management will be 10 to 13 percent.

        Interest Rate Risk.    Changes in interest rates affect interest income earned on the Company's cash equivalents and investments, as well as interest expense on variable interest rate borrowings under the Company's credit facility with Deutsche Bank AG and Citigroup Global Markets Inc. dated April 30, 2008 (the "2008 Credit Facility"). Based on the amount of cash equivalents and investments and the borrowing levels under the 2008 Credit Facility as of March 31, 2009, a hypothetical 10 percent increase or decrease in the interest rate associated with these instruments, with all other variables held constant, would not materially affect the Company's future earnings and cash outflows.

Historical—Liquidity and Capital Resources

        Operating Activities.    The Company reported net cash provided by operating activities of $12.4 million and $58.6 million for the Prior Year Quarter and Current Year Quarter, respectively. The $46.2 million increase in operating cash flows from the Prior Year Quarter to the Current Year Quarter is primarily attributable to the shift of restricted cash to restricted investments, which results in an operating cash flow source that is directly offset by an investing cash flow use. During the Prior Year Quarter, $10.9 million of restricted cash was shifted to restricted investments as compared to the Current Year Quarter in which $37.5 million of restricted cash was shifted to restricted investments, which results in a net increase in operating cash flows of $26.6 million. The Prior Year Quarter included restricted cash funding of $15.0 million for a risk radiology contract, the run-out of net contract liabilities associated with terminated Commercial contracts of $11.4 million and the net funding of restricted cash of $10.6 million associated with the Company's regulated entities. Partially offsetting these items is the decrease in Segment Profit of $12.6 from the Prior Year Quarter and other net unfavorable variances of $4.8 million primarily associated with working capital changes.

        During the Current Year Quarter, the Company's restricted cash decreased $64.4 million. The change in restricted cash is attributable to the shift of $37.5 million in restricted cash to restricted investments, a reduction in restricted cash of $22.9 million associated with the Company's regulated entities and other net decreases of $4.0 million. In regards to the decrease in restricted cash associated with the Company's regulated entities, $24.0 million is offset by changes in other assets and liabilities, primarily medical claims payable and other medical liabilities, thus having no impact on operating cash flows. Partially offsetting these reductions is the net funding of $1.1 million in additional restricted cash associated with the Company's regulated entities.

        Investing Activities.    The Company utilized $8.0 million and $5.3 million during the Prior Year Quarter and Current Year Quarter, respectively, for capital expenditures. The majority of the decrease in capital expenditures of $2.7 million is attributable to capital expenditures incurred during the Prior Year Quarter of $1.5 million associated with the Maricopa Contract. Most of the remainder of the

29


Table of Contents


capital expenditures for the Prior Year Quarter and the majority of capital expenditures for the Current Year Quarter related to management information systems and related equipment.

        During the Prior Year Quarter, the Company received net cash of $18.1 million from the net maturity of "available for sale" investments. During the Current Year Quarter, the Company used net cash of $29.0 million for the purchase of "available for sale" investments. The net purchase of "available for sale" investments during the Current Year Quarter is primarily attributable to the shift of restricted cash of $37.5 million to restricted investments, partially offset by matured unrestricted investments that were not reinvested.

        During the Prior Year Quarter, the Company made the final working capital payment of $0.4 million related to the acquisition of ICORE Healthcare LLC.

        Financing Activities.    During the Prior Year Quarter, the Company repaid $4.2 million of indebtedness outstanding under the Company's credit agreement with Deutsche Bank AG dated January 5, 2004, as amended (the "Credit Agreement") and made payments on capital lease obligations of $0.1 million. In addition, the Company received $4.0 million from the exercise of stock options and warrants and had other net unfavorable items of $1.5 million.

        During the Current Year Quarter, the Company paid $59.5 million for repurchase of treasury stock under the Company's share repurchase program. In addition, the Company received $0.9 million from the exercise of stock options and warrants and had other net favorable items of $0.7 million.

Outlook—Liquidity and Capital Resources

        Liquidity.    During 2009, the Company expects to fund its estimated capital expenditures of $20 to $30 million with cash from operations. The Company does not anticipate that it will need to draw on amounts available under the 2009 Credit Facility (as defined below) for its operations, capital needs or debt service in 2009. The Company also currently expects to have adequate liquidity to satisfy its existing financial commitments over the periods in which they will become due. The Company maintains its current investment strategy of investing in a diversified, high quality, liquid portfolio of investments and continues to closely monitor the situation in the financial and credit markets. The Company estimates that it has no risk of any material permanent loss on its investment portfolio; however, there can be no assurance that the Company will not experience any such losses in the future.

        Off-Balance Sheet Arrangements.    As of March 31, 2009, the Company has no material off-balance sheet arrangements.

        2008 Credit Facility.    On April 30, 2008, the Company's Credit Agreement was terminated, and the Company entered into a credit facility with Deutsche Bank AG and Citigroup Global Markets Inc. that provided for a $100.0 million Revolving Loan Commitment for the issuance of letters of credit for the account of the Company with a sublimit of up to $30.0 million for revolving loans (the "2008 Credit Facility"). Borrowings under the 2008 Credit Facility, if any, matured on April 29, 2009. The 2008 Credit Facility was guaranteed by substantially all of the subsidiaries of the Company and was secured by substantially all of the assets of the Company and the subsidiary guarantors.

        Under the 2008 Credit Facility, the annual interest rate on Revolving Loan borrowings bear interest at a rate equal to the sum of (i) a borrowing margin of 1.00 percent plus (ii) (A) in the case of U.S. dollar denominated loans, the higher of the prime rate or one-half of one percent in excess of the overnight "federal funds" rate, or (B) in the case of Eurodollar denominated loans, an interest rate which is a function of the Eurodollar rate for the selected interest period. The Company has the option to borrow in U.S. dollar denominated loans or Eurodollar denominated loans at its discretion. Letters of Credit issued under the Revolving Loan Commitment bear interest at the rate of 1.125 percent. The

30


Table of Contents


commitment commission on the 2008 Credit Facility was 0.375 percent of the unused Revolving Loan Commitment.

        On April 29, 2009, the Company entered into an amendment to the 2008 Credit Facility with Deutsche Bank AG, Citibank, N.A., and Bank of America, N.A. that provides for an $80.0 million Revolving Loan Commitment for the issuance of letters of credit for the account of the Company with a sublimit of up to $30.0 million for revolving loans (the "2009 Credit Facility"). Borrowings under the 2009 Credit Facility will mature on April 28, 2010. The 2009 Credit Facility is guaranteed by substantially all of the subsidiaries of the Company and is secured by substantially all of the assets of the Company and the subsidiary guarantors.

        Under the 2009 Credit Facility, the annual interest rate on Revolving Loan borrowings bear interest at a rate equal to (i) in the case of U.S. dollar denominated loans, the sum of a borrowing margin of 2.25 percent plus the higher of the prime rate or one-half of one percent in excess of the overnight "federal funds" rate, or (ii) in the case of Eurodollar denominated loans, the sum of a borrowing margin of 3.25 percent plus the Eurodollar rate for the selected interest period. The Company has the option to borrow in U.S. dollar denominated loans or Eurodollar denominated loans at its discretion. Letters of Credit issued under the Revolving Loan Commitment bear interest at the rate of 3.375 percent. The commitment commission on the 2009 Credit Facility is 0.625 percent of the unused Revolving Loan Commitment.

        Restrictive Covenants in Debt Agreements.    The 2009 Credit Facility contains covenants that limit management's discretion in operating the Company's business by restricting or limiting the Company's ability, among other things, to:

        These restrictions could adversely affect the Company's ability to finance future operations or capital needs or engage in other business activities that may be in the Company's interest.

        The 2009 Credit Facility also requires the Company to comply with specified financial ratios and tests. Failure to do so, unless waived by the lenders under the 2009 Credit Facility pursuant to their terms, would result in an event of default under such credit facilities.

        Net Operating Loss Carryforwards.    The Company estimates that it had reportable federal NOLs as of December 31, 2008 of approximately $124.5 million available to reduce future federal taxable income. These estimated NOLs expire in 2011 through 2020 and are subject to examination and adjustment by the IRS. In addition, the Company's utilization of such NOLs is subject to limitation under Internal Revenue Code Section 382, which affects the timing of the use of these NOLs. At this time, the Company does not believe these limitations will limit the Company's ability to use any federal NOLs before they expire. Although the Company has NOLs that may be available to offset future taxable income, the Company may be subject to Federal Alternative Minimum Tax.

31


Table of Contents

        As of December 31, 2008, the Company's valuation allowances against deferred tax assets were $9.4 million, mostly relating to uncertainties regarding the eventual realization of certain state NOLs and other state deferred tax assets. Determination of the amount of deferred tax assets considered realizable required significant judgment and estimation. Changes in these estimates in the future could materially affect the Company's financial condition and results of operations.

Recent Accounting Pronouncements

        In September 2006, the Financial Accounting Standards Board ("FASB") issued Statement of Financial Accounting Standards ("SFAS") No. 157 ("SFAS 157"), which provides guidance for using fair value to measure assets and liabilities. It also responds to investors' requests for expanded information about the extent to which companies measure assets and liabilities at fair value, the information used to measure fair value and the effect of fair value measurements on earnings. SFAS 157 applies whenever other standards require (or permit) assets or liabilities to be measured at fair value, and does not expand the use of fair value in any new circumstances. SFAS 157 is effective for fiscal years beginning after November 15, 2007. In February 2008, the FASB issued FASB Staff Position No. 157-2, Effective Date of FASB Statement No. 157 ("FSP 157-2"), which delays the effective date of SFAS 157 by one year for all non-financial assets and non-financial liabilities, except those that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). On January 1, 2008, the Company adopted SFAS 157 for financial assets and liabilities. The adoption did not have a material impact on the consolidated financial statements. On January 1, 2009, the Company adopted SFAS 157 for non-financial assets and non-financial liabilities. The adoption did not have a material impact on the consolidated financial statements.

        In December 2007, the FASB issued SFAS No. 141(R) "Business Combinations" ("SFAS 141(R)") and SFAS No. 160, "Non-controlling Interests in Consolidated Financial Statements" ("SFAS 160"). SFAS 141(R) requires the acquiring entity in a business combination to record all assets acquired and liabilities assumed at their respective acquisition-date fair values and changes other practices under SFAS 141, some of which could have a material impact on how the Company accounts for future business combinations. SFAS 141(R) also requires additional disclosure of information surrounding a business combination, such that users of the entity's financial statements can fully understand the nature and financial impact of the business combination. SFAS 160 requires entities to report non-controlling (minority) interests in subsidiaries as equity in the consolidated financial statements. The Company adopted SFAS 141(R) and SFAS 160 simultaneously in the Company's year beginning January 1, 2009. Prior to 2009 and in accordance with American Institute of Certified Public Accountants ("AICPA") Statement of Position ("SOP") 90-7, "Financial Reporting by Entities in Reorganization Under the Bankruptcy Code" ("SOP 90-7"), reversals of both valuation allowances and unrecognized tax benefits with respect to years prior to the Company's reorganization were recorded to goodwill. All other reversals of these balances were recorded as reductions to income tax expense. As a result of the implementation of SFAS 141(R), beginning in 2009 all reversals of valuation allowances and unrecognized tax benefits are reflected as reductions to income tax expense, even if related to years prior to the Company's reorganization. The adoption of SFAS 160 did not have a material impact on the consolidated financial statements.

Item 3.    Quantitative and Qualitative Disclosures About Market Risk.

        Changes in interest rates affect interest income earned on the Company's cash equivalents and restricted cash and investments, as well as interest expense on variable interest rate borrowings under the 2008 Credit Facility. Based on the Company's investment balances, and the borrowing levels under the 2008 Credit Facility as of March 31, 2009, a hypothetical 10 percent increase or decrease in the interest rate associated with these instruments, with all other variables held constant, would not materially affect the Company's future earnings and cash outflows.

32


Table of Contents


Item 4.    Controls and Procedures.

        a)    The Company's management evaluated, with the participation of the Company's principal executive and principal financial officers, the effectiveness of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) under the Exchange Act), as of March 31, 2009. Based on their evaluation, the Company's principal executive and principal financial officers concluded that the Company's disclosure controls and procedures were effective as of March 31, 2009.

        b)    Under the supervision and with the participation of management, including the Company's principal executive and principal financial officers, the Company has determined that there has been no change in the Company's internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that occurred during the Company's quarter ended March 31, 2009 that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

33


Table of Contents


PART II—OTHER INFORMATION

Item 1.    Legal Proceedings.

        The management and administration of the delivery of specialty managed healthcare entails significant risks of liability. From time to time, the Company is subject to various actions and claims arising from the acts or omissions of its employees, network providers or other parties. In the normal course of business, the Company receives reports relating to deaths and other serious incidents involving patients whose care is being managed by the Company. Such incidents occasionally give rise to malpractice, professional negligence and other related actions and claims against the Company or its network providers. Many of these actions and claims received by the Company seek substantial damages and therefore require the Company to incur significant fees and costs related to their defense. The Company is also subject to or party to certain class actions, litigation and claims relating to its operations or business practices. In the opinion of management, the Company has recorded reserves that are adequate to cover litigation, claims or assessments that have been or may be asserted against the Company, and for which the outcome is probable and reasonably estimable. Management believes that the resolution of such litigation and claims will not have a material adverse effect on the Company's financial condition or results of operations; however, there can be no assurance in this regard.

Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds.

        On July 30, 2008 the Company's board of directors approved a stock repurchase plan which authorizes the Company to purchase up to $200 million of its outstanding common stock through January 31, 2010. Stock repurchases under the program may be executed through open market repurchases, privately negotiated transactions, accelerated share repurchases or other means. The board of directors authorized management to execute stock repurchase transactions from time to time and in such amounts and via such methods as management deems appropriate. The stock repurchase program may be limited or terminated at any time without prior notice. Pursuant to this program, the Company made open market purchases of 1,799,933 shares of the Company's common stock at an average share price of $34.32 per share for an aggregate cost of $61.8 million (excluding broker commissions) during the three months ended March 31, 2009. As of March 31, 2009, the amount of stock repurchases that remained under the program was $2.2 million and such remaining repurchases were made during the period subsequent to March 31, 2009, completing the repurchase program as of April 7, 2009.

        Following is a summary of stock repurchases made from January 1, 2009 through the completion of the repurchase program on April 7, 2009:

Period
  Total number
of Shares
Purchased
  Average
Price Paid
per Share(2)
  Total Number of Shares
Purchased as Part of Publicly
Announced Plans or Programs
  Approximate Dollar Value
(in thousands) of Shares that
May Yet Be Purchased
Under the Plan(1)(2)
 

January 1-31, 2009

    117,200   $ 37.36     117,200   $ 59,585  

February 1-28, 2009

    422,000   $ 34.72     422,000     44,932  

March 1-31, 2009

    1,260,733   $ 33.91     1,260,733     2,185  

April 1-7, 2009

    60,026   $ 36.42     60,026      
                     

    1,859,959           1,859,959      
                     

(1)
Excludes amounts that could be used to repurchase shares acquired under the Company's equity incentive plans to satisfy withholding tax obligations of employees and non-employee directors upon the vesting of restricted stock units.

(2)
Excludes broker commissions and transaction fees.

34


Table of Contents

Item 3.    Defaults Upon Senior Securities.

        None.

Item 4.    Submission of Matters to a Vote of Security Holders.

        None.

Item 5.    Other Information.

        (i) 2009 Credit Facility:    On April 29, 2009, the Company entered into an amendment to the 2008 Credit Facility with Deutsche Bank AG, Citibank, N.A., and Bank of America, N.A. that provides for an $80.0 million Revolving Loan Commitment for the issuance of letters of credit for the account of the Company with a sublimit of up to $30.0 million for revolving loans (the "2009 Credit Facility"). Borrowings under the 2009 Credit Facility will mature on April 28, 2010. The 2009 Credit Facility is guaranteed by substantially all of the subsidiaries of the Company and is secured by substantially all of the assets of the Company and the subsidiary guarantors.

        Under the 2009 Credit Facility, the annual interest rate on Revolving Loan borrowings bear interest at a rate equal to (i) in the case of U.S. dollar denominated loans, the sum of a borrowing margin of 2.25 percent plus the higher of the prime rate or one-half of one percent in excess of the overnight "federal funds" rate, or (ii) in the case of Eurodollar denominated loans, the sum of a borrowing margin of 3.25 percent plus the Eurodollar rate for the selected interest period. The Company has the option to borrow in U.S. dollar denominated loans or Eurodollar denominated loans at its discretion. Letters of Credit issued under the Revolving Loan Commitment bear interest at the rate of 3.375 percent. The commitment commission on the 2009 Credit Facility is 0.625 percent of the unused Revolving Loan Commitment.

        (ii) Managed Behavioral Health Contract:    As previously reported, the Company has a managed behavioral healthcare contract with a customer that extends through June 30, 2009 and generated net revenues of $90.8 million for the year ended December 31, 2008. On April 30, 2009, the Company and its customer entered into a new contract with a term expiring June 30, 2014, terminable without cause upon 180 days' notice after the third anniversary of the contract. The contract is expected to generate revenues in excess of $90 million during fiscal 2009.

Item 6.    Exhibits

  4.1   Second Amendment to Credit Agreement, dated as of April 29, 2009, among Magellan Health Services, Inc., various lenders and Deutsche Bank AG New York Branch, as administrative agent.

 

31.1

 

Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes Oxley Act of 2002.

 

31.2

 

Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

32.1

 

Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

32.2

 

Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

35


Table of Contents


SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: April 30, 2009   MAGELLAN HEALTH SERVICES, INC.
(Registrant)

 

 

By:

 

/s/ JONATHAN N. RUBIN

Jonathan N. Rubin
Executive Vice President and Chief Financial
Officer (Principal Financial Officer and Duly
Authorized Officer)

36




Exhibit 4.1

 

SECOND AMENDMENT TO CREDIT AGREEMENT

 

SECOND AMENDMENT TO CREDIT AGREEMENT (this “Second Amendment”), dated as of April 29, 2009, among Magellan Health Services, Inc., a Delaware corporation (the “Borrower”), certain Subsidiaries of the Borrower who are Subsidiary Guarantors, the lenders party to the Credit Agreement referred to below (the “Lenders”), Bank of America, N.A. (“BofA”) (which, upon the occurrence of the Second Amendment Effective Date (as hereinafter defined), will become a Lender) and Deutsche Bank AG New York Branch, as administrative agent (in such capacity, the “Administrative Agent”). Unless otherwise indicated, all capitalized terms used herein and not otherwise defined herein shall have the respective meanings provided such terms in the Credit Agreement.

 

W I T N E S S E T H :

 

WHEREAS, the Borrower, the Lenders and the Administrative Agent are parties to a Credit Agreement, dated as of April 30, 2008 and amended as of November 12, 2008 (as so amended, the “Credit Agreement”);

 

WHEREAS, the Borrower has requested, and BofA has agreed, that upon the occurrence of the Second Amendment Effective Date, BofA shall become a Lender under (and for all purposes of) the Credit Agreement and the other Credit Documents with an initial Revolving Loan Commitment as set forth on Schedule I hereto; and

 

WHEREAS, the Borrower has requested, and the Lenders and BofA have agreed, subject to the terms and conditions of this Second Amendment, to amend the Credit Agreement as herein provided;

 

NOW, THEREFORE, it is agreed:

 

I.                                         Amendments and Agreements with respect to the Credit Agreement.

 

1.                                       Schedule I and Schedule V to the Credit Agreement are hereby deleted in their entirety and replaced by Schedule I and Schedule V attached hereto, respectively.

 

2.                                       Schedule X to the Credit Agreement is hereby amended by adding the following information thereon:

 

“Bank of America, N.A.

Bank of America, N.A.

 

Bank of America Corporate Center

 

100 North Tyron Street

 

Charlotte, North Carolina 28255

 

Attention: [            ]

 

Telephone No.: [                  ]

 

Telecopier No.: [                  ]”.

 



 

3.                                       The parties hereto acknowledge and agree that (i) notwithstanding anything to the contrary contained in the Credit Agreement, the Total Revolving Loan Commitment shall remain in effect on the Second Amendment Effective Date but shall be reduced on the Second Amendment Effective Date to $80,000,000 (as such amount may be further reduced from time to time thereunder or terminated in accordance with the terms of the Credit Agreement), (ii) the Revolving Loan Commitment of each Lender (including BofA) on the Second Amendment Effective Date shall be as set forth on Schedule I hereto (as each such amount may be adjusted from time to time in accordance with the terms of the Credit Agreement), (iii) upon the occurrence of the Second Amendment Effective Date, BofA shall become a Lender under (and for all purposes of) the Credit Agreement and the other Credit Documents with an initial Revolving Loan Commitment as set forth on such Schedule I and (iv) on the Second Amendment Effective Date and with respect to all outstanding Letters of Credit, there shall be an automatic adjustment to the participations therein pursuant to Section 2.04 of the Credit Agreement to reflect the new RL Percentages of the Lenders immediately after giving effect to this Second Amendment.

 

4.                                       Section 1.08(a) of the Credit Agreement is hereby amended by inserting the text “the sum of the Applicable Margin as in effect from time to time plus” immediately after the text “which shall be equal to” appearing in such Section.

 

5.                                       Section 2.05(a) of the Credit Agreement is hereby amended by inserting the text “plus the Applicable Margin as in effect from time to time for Base Rate Loans” immediately after each occurrence of the text “equal to the Base Rate in effect from time to time” appearing in such Section.

 

6.                                       Section 7.05(a) of the Credit Agreement is hereby amended by inserting the following new sentence immediately after the first sentence thereof:

 

“The consolidated balance sheet of the Borrower as at December 31, 2008, and the related consolidated statements of income, cash flows and retained earnings of the Borrower for the fiscal year ended December 31, 2008, copies of which have been furnished to the Lenders prior to the Second Amendment Effective Date, present fairly in all material respects the consolidated financial position of the Borrower at the dates of such balance sheet and the consolidated results of the operations of the Borrower for the period covered thereby.”

 

7.                                       Section 7.05(b) of the Credit Agreement is hereby amended by deleting the word “and” appearing immediately after the word “Transaction” appearing in the first sentence thereof and inserting the text “and on and as of the Second Amendment Effective Date and (in each case)” in lieu thereof.

 

8.                                       Section 7.05(d) of the Credit Agreement is hereby amended by inserting the following text immediately after the last sentence thereof:

 

“The New Projections delivered to the Administrative Agent and the Lenders prior to the Second Amendment Effective Date have been prepared in good faith and are based on reasonable assumptions, and there are no statements or conclusions in the

 

2



 

Projections which are based upon or include information known to the Borrower to be misleading in any material respect or which fail to take into account material information known to the Borrower regarding the matters reported therein.  On the Second Amendment Effective Date, the Borrower believes that the New Projections are reasonable and attainable, it being recognized by the Lenders, however, that projections as to future events are not to be viewed as facts and that the actual results during the period or periods covered by the New Projections may differ from the projected results and such differences may be material.”

 

9.                                       Section 7.05(e) of the Credit Agreement is hereby amended by replacing the text “December 31, 2007” appearing therein with the text “December 31, 2008”.

 

10.                                 Sections 7.14(a) and (b) of the Credit Agreement are hereby amended by deleting the text “Effective Date” in each place such text appears therein and inserting the text “Second Amendment Effective Date” in lieu thereof in each such place.

 

11.                                 Section 9.09 of the Credit Agreement is hereby amended by replacing the text “3.00:1.00” appearing therein with the text “2.50:1.00”.

 

12.                                 The definitions of “Applicable Commitment Commission Percentage”, “Applicable Margin”, “Lender Default” and “Revolving Loan Maturity Date” appearing in Section 11 of the Credit Agreement are hereby restated in their entirety as follows:

 

Applicable Commitment Percentage” shall mean, on any day, (i) for periods prior to the Second Amendment Effective Date, 0.375% per annum, and (ii) for periods from and after the Second Amendment Effective Date, 0.625% per annum.

 

Applicable Margin” shall mean, on any day, with respect to Loans (x) maintained as Eurodollar Loans (i) for periods prior to the Second Amendment Effective Date, 1.00% per annum, and (ii) for periods from and after the Second Amendment Effective Date, 3.25% per annum, and (y) maintained as Base Rate Loans (i) for periods prior to the Second Amendment Effective Date, 0% per annum, and (ii) for periods from and after the Second Amendment Effective Date, 2.25% per annum.

 

Lender Default” shall mean, as to any Lender, as reasonably determined by the Administrative Agent, that such Lender has (a) failed to fund any portion of its Loans or participations in Letters of Credit (including its portion of any unreimbursed payment under Section 2.04(c)) or Swingline Loans (including its portion of any Mandatory Borrowing) within three Business Days of the date required to be funded by it hereunder (or, for purposes of the last sentence of Section 1.01(b) and Section 2.03(c), such Lender has failed to fund any portion of its Loans or participations in Letters of Credit or Swingline Loans on the date required to be funded by it hereunder), (b) notified the Borrower, the Administrative Agent, any Issuing Lender, the Swingline Lender or any Lender in writing that it does not intend to comply with any of its funding obligations under

 

3



 

this Agreement or has made a public statement to the effect that it does not intend to comply with its funding obligations under this Agreement or under other agreements in which it commits to extend credit, (c) failed, within three Business Days after request by the Administrative Agent, to confirm that it will comply with the terms of this Agreement relating to its obligations to fund prospective Loans and participations in then outstanding Letters of Credit and Swingline Loans, (d) otherwise failed to pay over to the Administrative Agent, any Issuing Lender, the Swingline Lender or any other Lender any other amount required to be paid by it under this Agreement within three Business Days of the date when due, unless the subject of a good faith dispute, or (e) (i) become or is insolvent or has a parent company that has become or is insolvent or (ii) become the subject of a bankruptcy or insolvency proceeding, or has had a receiver, conservator, trustee or custodian appointed for it, or has taken any action in furtherance of, or indicating its consent to, approval of or acquiescence in any such proceeding or appointment or has a parent company that has become the subject of a bankruptcy or insolvency proceeding, or has had a receiver, conservator, trustee or custodian appointed for it, or has taken any action in furtherance of, or indicating its consent to, approval of or acquiescence in any such proceeding or appointment.

 

Revolving Loan Maturity Date” shall mean April 28, 2010.

 

13.                                 Section 11 of the Credit Agreement is hereby further amended by inserting the following new definitions in the correct alphabetical order:

 

New Projections” shall mean the projections, dated March 4, 2009, prepared by or on behalf of the Borrower in connection with the budget delivered by the Borrower pursuant to and in accordance with Section 8.01(d) of this Agreement, as such “New Projections” were delivered to each of the Administrative Agent and Citibank, N.A., on March 4, 2009 and to Bank of America, N.A., on March 31, 2009.

 

Second Amendment” shall mean the Second Amendment to this Agreement, dated as of April 29, 2009, among the Borrower, the Lenders and the Administrative Agent.

 

Second Amendment Effective Date” shall have the meaning set forth in the Second Amendment.

 

14.                                 Section 13.12(a) of the Credit Agreement is hereby amended by (i) deleting the word “or” appearing immediately before clause (v) of the first proviso of said Section and (ii) deleting the semi-colon appearing at the end of clause (v) of the first proviso of said Section and inserting the text “, or (vi) only for so long as either (x) no Lender is a Defaulting Lender or (y) the only Lenders party to this Agreement are the Lenders on the Second Amendment Effective Date and their respective Affiliates, in either case, amend, modify or waive any provision of Section 9.08 or 9.09;” in lieu thereof.

 

4



 

15.                                 Section 13.12(b) of the Credit Agreement is hereby amended by deleting text “clauses (i) through (v)” appearing therein and inserting the text “clauses (i) through (vi)” in lieu thereof.

 

II.                                     Miscellaneous Provisions.

 

1.                                       In order to induce the Lenders to enter into this Second Amendment, the Borrower hereby represents and warrants that:

 

(i)                                     no Default or Event of Default exists as of the Second Amendment Effective Date, both immediately before and immediately after giving effect to this Second Amendment on such date;

 

(ii)                                  all of the representations and warranties contained in the Credit Agreement and in the other Credit Documents are true and correct in all material respects on the Second Amendment Effective Date, both immediately before and immediately after giving effect to this Second Amendment on such date, with the same effect as though such representations and warranties had been made on and as of the Second Amendment Effective Date (it being understood and agreed that any representation or warranty which by its terms is made as of a specified date shall be required to be true and correct in all material respects only as of such specified date);

 

(iii)                              each Credit Party has the corporate, partnership or limited liability partnership power and authority, as the case may be, to execute, deliver and perform the terms and provisions of this Second Amendment and has taken all necessary corporate, partnership or limited liability partnership action, as the case may be, to authorize the execution, delivery and performance by it of this Second Amendment, and each Credit Party has duly executed and delivered this Second Amendment, and this Second Amendment constitutes its legal, valid and binding obligation enforceable in accordance with its terms, except to the extent that the enforceability hereof may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or other similar laws generally affecting creditors’ rights and by equitable principles (regardless of whether enforcement is sought in equity or at law);

 

(iv)                              neither the execution, delivery or performance by any Credit Party of this Second Amendment, nor compliance by it with the terms and provisions thereof, (i) will contravene or violate any provision of any applicable law, statute, rule or regulation (including, without limitation, any Health Care Law) or any order, writ, injunction or decree of any court or governmental instrumentality, (ii) will conflict with or result in any breach of any of the terms, covenants, conditions or provisions of, or constitute a default under, or result in the creation or imposition of (or the obligation to create or impose) any Lien (except pursuant to the Security Documents) upon any portion of the property or assets of any Credit Party or any of its Subsidiaries pursuant to the terms of any indenture, mortgage, deed of trust, credit agreement or loan agreement, or any other material agreement, contract or instrument, in each case to which any Credit Party or any of its Subsidiaries is a party or by which it or any of its property or assets is bound or to

 

5



 

which it may be subject, or (iii) will contravene or violate any provision of the certificate or articles of incorporation, certificate of formation, limited liability company agreement or by-laws (or equivalent organizational documents), as applicable, of any Credit Party or any of its Subsidiaries;

 

(v)                                 no order, consent, approval, license, authorization or validation of, or filing, recording or registration with (except for those that have otherwise been obtained or made on or prior to the Second Amendment Effective Date and which remain in full force and effect on the Second Amendment Effective Date), or exemption by, any governmental or public body or authority is required to be obtained or made by, or on behalf of, any Credit Party to authorize, or is required to be obtained or made by, or on behalf of, any Credit Party in connection with, (i) the execution, delivery and performance of this Second Amendment or (ii) the legality, validity, binding effect or enforceability of this Second Amendment; and

 

(vi)                              no Loans are outstanding on the Second Amendment Effective Date.

 

2.                                       Each Credit Party acknowledges and agrees that the Credit Agreement (as amended by this Second Amendment) and each other Credit Document to which such Credit Party is a party, and all Obligations thereunder  are valid and enforceable against the Borrower and the Subsidiary Guarantors (as applicable) in every respect and all of the terms and conditions thereof are legally binding upon the Borrower and the Subsidiary Guarantors (as applicable), in each case all without offset, counterclaims or defenses of any kind and that each of the waiver of claims and defenses granted by each Credit Party under the Credit Documents to which such Credit Party is a party is reaffirmed and ratified.

 

3.                                       By executing and delivering a counterpart hereof, each Credit Party hereby agrees that all Loans, Letters of Credit and other Obligations (in each case, under each Credit Document) shall be fully guaranteed pursuant to the Subsidiaries Guaranty in accordance with the terms and provisions thereof and shall be fully secured pursuant to the Security Documents.

 

4.                                       This Second Amendment is limited as specified and shall not constitute a modification, acceptance or waiver of any other provision of the Credit Agreement or any other Credit Document.

 

5.                                       This Second Amendment may be executed in any number of counterparts and by the different parties hereto on separate counterparts, each of which counterparts when executed and delivered shall be an original, but all of which shall together constitute one and the same instrument. A complete set of counterparts shall be lodged with the Borrower and the Administrative Agent.

 

6.                                       THIS SECOND AMENDMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE CONSTRUED IN ACCORDANCE WITH AND GOVERNED BY THE INTERNAL LAW OF THE STATE OF NEW YORK WITHOUT REGARD TO CONFLICTS OF LAW PRINCIPLES.

 

6



 

7.                                       This Second Amendment shall become effective on the date (the “Second Amendment Effective Date”) when each of the following conditions shall have been satisfied:

 

(i)                                     the Borrower, each Subsidiary Guarantor, each of the Lenders and BofA (BofA, together with the Lenders, are collectively referred to herein as the “Commitment Parties”) shall have signed a counterpart hereof (whether the same or different counterparts) and shall have delivered (including by way of facsimile or other electronic transmission) the same to White & Case LLP, 1155 Avenue of the Americas, New York, NY 10036 Attention:  May Yip (facsimile number: 212-354-8113 / e-mail address: myip@whitecase.com);

 

(ii)                                  the Borrower and its Subsidiaries shall have no outstanding preferred equity, Indebtedness or contingent liabilities, except as shall be permitted under the Credit Agreement;

 

(iii)                              all necessary governmental (domestic and foreign) and material third party approvals and/or consents in connection with this Second Amendment (and the payment of all fees, costs and expenses in connection herewith) and the other transactions contemplated hereby shall have been obtained and remain in effect;

 

(iv)                              there shall not exist any judgment, order, injunction or other restraint prohibiting or imposing materially adverse conditions upon any Credit Document or this Second Amendment or the transactions contemplated hereby or thereby or otherwise referred to herein or therein;

 

(v)                                 since December 31, 2008, nothing shall have occurred (and no Commitment Party shall have become aware of any facts or conditions not previously known) which any Commitment Party shall determine has had, or could reasonably be expected to have, a Material Adverse Effect;

 

(vi)                              no litigation by any entity (private or governmental) shall be pending or threatened with respect to any Credit Document or this Second Amendment, or which any Commitment Party shall determine has had, or could reasonably be expected to have, a Material Adverse Effect;

 

(vii)                           all costs, fees, expenses (including, without limitation, legal fees and expenses) and other compensation contemplated hereby and by the Commitment Letter and related Fee Letters each dated April 14, 2009 and entered into with the Borrower in connection with this Second Amendment, and payable to the Commitment Parties shall have been paid to the extent due;

 

(viii)                        the Commitment Parties shall have received (x) from Weil, Gotshal & Manges LLP, special counsel to the Credit Parties, an opinion addressed to the Administrative Agent, the Collateral Agent and each of the Lenders and dated the Second Amendment Effective Date substantially in the form of Exhibit E to the Credit Agreement and otherwise reasonably satisfactory to the Commitment Parties, (y) a solvency certificate from the chief financial officer of the Borrower substantially in the form of Exhibit J to the Credit Agreement and otherwise reasonably satisfactory to the

 

7



 

Commitment Parties and (z) certificates of insurance complying with the requirements of Section 8.03 of the Credit Agreement for the business and properties of the Borrower and its Subsidiaries, in form and substance reasonably satisfactory to the Commitment Parties;

 

(ix)                                there shall have been delivered to the Administrative Agent for the account of each of the Lenders that has requested same the appropriate Revolving Note executed by the Borrower and, if requested by the Swingline Lender, the Swingline Note executed by the Borrower, in each case in the amount, maturity and as otherwise provided in the Credit Agreement;

 

(x)                                   the Administrative Agent shall have received a certificate, dated the Second Amendment Effective Date and signed on behalf of the Borrower by the chairman of the board, the chief executive officer, the chief financial officer, the president or any vice president of the Borrower, certifying on behalf of the Borrower that all of the conditions in clauses (ii), (iii), (iv), (v), (vi), (xiv) and (xv) of this Section II.7 have been satisfied on such date;

 

(xi)                                the Administrative Agent shall have received true and correct copies of the December 31, 2008 historical consolidated financial statements and the New Projections referred to in Sections 7.05(a) and (d) of the Credit Agreement (as amended by this Second Amendment);

 

(xii)                             the Administrative Agent shall have received a certificate from each Credit Party, dated the Second Amendment Effective Date, signed by the chairman of the board, the chief executive officer, the president, the chief financial officer, the treasurer or any vice president of such Credit Party, and attested to by the secretary or any assistant secretary of such Credit Party, substantially in the form of Exhibit F to the Credit Agreement with appropriate insertions and changes, together with copies of the certificate or articles of incorporation and by-laws (or equivalent organizational documents), as applicable, of such Credit Party (but only to the extent that such charter documents have been amended or modified since the Effective Date or to the extent that any new Subsidiary has been formed since the Effective Date) and the resolutions of such Credit Party referred to in such certificate, and each of the foregoing shall be in form and substance reasonably acceptable to the Agents;

 

(xiii)                          all corporate, partnership, limited liability company and legal proceedings and all instruments and agreements in connection with the transactions contemplated by this Second Amendment shall be reasonably satisfactory in form and substance to the Commitment Parties, and the Administrative Agent shall have received all information and copies of all documents and papers, including records of corporate proceedings, governmental approvals, good standing certificates and bring-down telegrams or facsimiles, if any, which the Administrative Agent may have reasonably requested in connection therewith, such documents and papers where appropriate to be certified by proper corporate, partnership, limited liability company or governmental authorities;

 

8



 

(xiv)                         all representations and warranties herein and in the Credit Documents shall be true and correct in all material respects on and as of the Second Amendment Effective Date (although any representations and warranties which expressly relate to a given date or period shall be required to be true and correct in all material respects as of the respective date or for the respective period, as the case may be); and

 

(xv)                            no Default or Event of Default shall have occurred and be continuing on the Second Amendment Effective Date.

 

8.                                       From and after the Second Amendment Effective Date, all references in the Credit Agreement and each of the other Credit Documents to the Credit Agreement shall be deemed to be references to the Credit Agreement as modified hereby.

 

*        *        *

 

9



 

IN WITNESS WHEREOF, the parties hereto have caused their duly authorized officers to execute and deliver this Second Amendment as of the date first above written.

 

 

MAGELLAN HEALTH SERVICES, INC., as Borrower

 

 

 

By:

/s/ Jonathan Rubin

 

 

Name: Jonathan Rubin

 

 

Title: Chief Financial Officer

 

Signature page to Magellan Second Amendment

 


 

 

ADVANTAGE BEHAVIORAL SYSTEMS, INC.

 

ADVOCARE OF TENNESSEE, INC.

 

AGCA, INC.

 

CHARTER BEHAVIORAL HEALTH SYSTEM OF LAFAYETTE, INC.

 

CHARTER BEHAVIORAL HEALTH SYSTEM OF MASSACHUSETTS, INC.

 

CHARTER BEHAVIORAL HEALTH SYSTEM OF NEW MEXICO, INC.

 

CHARTER FAIRMOUNT BEHAVIORAL HEALTH SYSTEM, INC.

 

CHARTER HOSPITAL OF SANTA TERESA, INC.

 

CHARTER MEDICAL OF PUERTO RICO, INC.

 

CHARTER MOB OF CHARLOTTESVILLE, INC.

 

CHARTER NORTHRIDGE BEHAVIORAL HEALTH SYSTEM, INC.

 

CMG HEALTH, INC.

 

CONTINUUM BEHAVIORAL HEALTHCARE CORPORATION

 

GREEN SPRING HEALTH SERVICES, INC.

 

HUMAN AFFAIRS INTERNATIONAL OF PENNSYLVANIA, INC.

 

ICORE HEALTHCARE, LLC

 

MAGELLAN BEHAVIORAL HEALTH, INC.

 

MAGELLAN BEHAVIORAL OF MICHIGAN, INC.

 

MAGELLAN CAPITAL, INC.

 

MAGELLAN HEALTH SERVICES OF ARIZONA, INC.

 

MAGELLAN HEALTH SERVICES OF NEW MEXICO, INC.

 

MAGELLAN HRSC, INC.

 

MAGELLAN SUB CO. III, INC.

 

MANAGED CARE SERVICES MAINSTAY OF CENTRAL PENNSYLVANIA, INC.

 

MBC OF AMERICA, INC.

 

MBH of PUERTO RICO, INC.

 

MERIT BEHAVIORAL CARE CORPORATION

 

MERIT BEHAVIORAL CARE OF MASSACHUSETTS, INC.

 

NATIONAL IMAGING ASSOCIATES, INC.

 

Signature page to Magellan Second Amendment

 



 

 

ONCORE HEALTHCARE, LLC

 

P.P.C., INC.

 

PERSONAL PERFORMANCE CONSULTANTS OF NEW YORK, INC.

 

PPC GROUP, INC.,

 

each as a Subsidiary Guarantor

 

 

 

By:

/s/ Jonathan N. Rubin

 

 

Name: Jonathan N. Rubin

 

 

Title: Treasurer

 

 

 

 

MAGELLAN BEHAVIORAL HEALTH OF NEBRASKA, LLC

 

MAGELLAN CBHS HOLDINGS, LLC,

 

each as a Subsidiary Guarantor

 

 

 

 

By:

Magellan Behavioral Health, Inc.

 

 

as its Sole Member

 

 

 

 

By:

/s/ Jonathan N. Rubin

 

 

Name: Jonathan N. Rubin

 

 

Title: Treasurer

 

 

 

 

NATIONAL IMAGING ASSOCIATES OF PENNSYLVANIA, LLC,

 

as a Subsidiary Guarantor

 

 

 

 

By:

National Imaging Associates, Inc.

 

 

as a Member

 

 

 

 

By:

/s/ Jonathan N. Rubin

 

 

Name: Jonathan N. Rubin

 

 

Title:  Treasurer

 

Signature page to Magellan Second Amendment

 



 

 

PREMIER HOLDINGS, LLC

 

as a Subsidiary Guarantor

 

 

 

By:

AdvoCare of Tennessee, Inc,

 

 

as its Sole Member

 

 

 

 

By:

/s/ Jonathan N. Rubin

 

 

Name: Jonathan N. Rubin

 

 

Title: Treasurer

 

Signature page to Magellan Second Amendment

 



 

 

MAGELLAN FINANCIAL CAPITAL INC.,

 

as a Subsidiary Guarantor

 

 

 

By:

/s/ Daniel Gregoire

 

 

Name: Daniel Gregoire

 

 

Title: Vice President

 

Signature page to Magellan Second Amendment

 



 

 

DEUTSCHE BANK AG NEW YORK BRANCH

 

Individually and as Administrative Agent

 

 

 

 

 

By:

/s/ Ming K. Chu

 

 

Name: Ming K. Chu

 

 

Title: Vice President

 

 

 

 

By:

/s/ Douglas J. Weir

 

 

Name: Douglas J. Weir

 

 

Title: Director

 

Signature page to Magellan Second Amendment

 



 

 

CITIBANK, N.A.

 

 

 

 

 

By:

/s/ Allen Fisher

 

 

Name: Allen Fisher

 

 

Title: Vice President

 

Signature page to Magellan Second Amendment

 



 

 

BANK OF AMERICA, N.A.

 

 

 

 

 

By:

/s/ Alysa Trakas

 

 

Name: Alysa Trakas

 

 

Title: Vice President

 

Signature page to Magellan Second Amendment

 



 

Schedule I

 

Lender

 

Revolving Loan
Commitment

 

Deutsche Bank AG New York Branch

 

$

40,000,000

 

Citibank, N.A.

 

$

20,000,000

 

Bank of America, N.A.

 

$

20,000,000

 

 

 

 

 

TOTAL:

 

$

80,000,000

 

 



 

Schedule V

 

See attached.

 


 

SUBSIDIARIES

 

NAME OF CORPORATION(3)

 

CREDIT
PARTY

 

ORG #

 

OWNER OF STOCK

 

TYPE OF
ORG.

 

% OF
OWNERSHIP

 

STATE
OF
INCORP

 

CORPORATE ADDRESS

 

BASIS FOR WHICH:
A) ANY WHOLLY-
OWNED SPECIFIED
SUBSIDIARY CANNOT
ENTER INTO ANY
CREDIT DOCUMENT OR
B) THE SHARES OF
CAPITAL STOCK OF ANY
DOMESTIC SUBSIDIARY
CANNOT BE PLEDGED
PURSUANT TO THE
PLEDGE AGREEMENT

Advantage Behavioral Systems, Inc.

 

X

 

968445

 

Green Spring Health Services, Inc.

 

Corp.

 

100%

 

PA

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

 

AdvoCare of Tennessee, Inc.

 

X

 

293427

 

Green Spring Health Services, Inc.

 

Corp.

 

100%

 

TN

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

 

AGCA, Inc.

 

X

 

747375

 

Merit Behavioral Care Corporation

 

Corp.

 

100%

 

PA

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

 

Arizona Biodyne, Inc.

 

 

 

02006937

 

Merit Behavioral Care Corporation

 

Corp

 

100%

 

AZ

 

6950 Columbia Gateway Drive
Columbia MD 21046

 

Regulated entity (stock can be pledged)

Charter Behavioral Health System of Lafayette, Inc.

 

X

 

33746720D

 

Magellan CBHS Holdings, LLC

 

Corp.

 

100%

 

LA

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

 

Charter Behavioral Health System of Massachusetts, Inc.

 

X

 

043255904

 

Magellan CBHS Holdings, LLC

 

Corp.

 

100%

 

MA

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

 

Charter Behavioral Health System of New Mexico, Inc.

 

X

 

1145010

 

Magellan CBHS Holdings, LLC

 

Corp.

 

100%

 

NM

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

 

Charter Fairmount Behavioral Health System, Inc.

 

X

 

859556

 

Magellan CBHS Holdings, LLC

 

Corp.

 

100%

 

PA

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

 

The Charter Heights Behavioral Health System Limited Partnership

 

 

 

2595104

 

Charter Behavioral Health System of New Mexico, Inc.

 

LP

 

67%

 

DE

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

As per JV Agreement, limited partnership interest can be pledged.

Charter Hospital of Santa Teresa, Inc.

 

X

 

1232701

 

Magellan CBHS Holdings, LLC

 

Corp.

 

100%

 

NM

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

 

Charter Medical of Puerto Rico, Inc.

 

X

 

n/a

 

Magellan CBHS Holdings, LLC

 

Corp.

 

100%

 

PR

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

Foreign Subsidiary (65% of stock can be pledged)

Charter MOB of Charlottesville, Inc.

 

X

 

0294278-7

 

Magellan CBHS Holdings, LLC

 

Corp.

 

100%

 

VA

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

 

Charter North Star Behavioral Health System, LLC

 

 

 

0315213

 

Magellan CBHS Holdings, LLC

 

LLC

 

57%

 

TN

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

As per JV Agreement, limited liability company interest can be pledged.

Charter Northridge Behavioral Health System, Inc.

 

X

 

0026964

 

Magellan CBHS Holdings, LLC

 

Corp.

 

100%

 

NC

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

 

CMG Health, Inc.

 

X

 

D02185023

 

Merit Behavioral Care Corporation

 

Corp.

 

100%

 

MD

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

 

Continuum Behavioral Healthcare Corporation

 

X

 

2420018

 

Merit Behavioral Care Corporation

 

Corp.

 

100%

 

DE

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

 

Green Spring Health Services, Inc.

 

X

 

2329667

 

Magellan Health Services, Inc.

 

Corp.

 

100%

 

DE

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

 

Human Affairs International of California, Inc. (3)

 

 

 

C1594157

 

Magellan Behavioral Health, Inc.

 

Corp.

 

100%

 

CA

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

Regulated entity (stock cannot be pledged)

 


(3) All entities are registered organizations With regard to numbers listed in parenthesis after entity names: (2) = Foreign Insurance Company; (3) = Regulated entity; and (4) = Non-Profit Entity.

 



 

NAME OF CORPORATION(3)

 

CREDIT
PARTY

 

ORG #

 

OWNER OF STOCK

 

TYPE OF
ORG.

 

% OF
OWNERSHIP

 

STATE
OF
INCORP

 

CORPORATE ADDRESS

 

BASIS FOR WHICH:
A) ANY WHOLLY-
OWNED SPECIFIED
SUBSIDIARY CANNOT
ENTER INTO ANY
CREDIT DOCUMENT OR
B) THE SHARES OF
CAPITAL STOCK OF ANY
DOMESTIC SUBSIDIARY
CANNOT BE PLEDGED
PURSUANT TO THE
PLEDGE AGREEMENT

Human Affairs International of Pennsylvania, Inc.

 

X

 

2735010

 

Magellan Behavioral Health, Inc.

 

Corp.

 

100%

 

PA

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

 

ICORE Healthcare, LLC

 

X

 

3617243

 

Green Spring Health Services, Inc.

 

LLC

 

100%

 

DE

 

6950 Columbia Gateway Drive
Columbia MD 21046

 

 

Magellan Behavioral Care of Iowa,
Inc. (3)

 

 

 

175503

 

Merit Behavioral Care Corporation

 

Corp.

 

100%

 

IA

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

Regulated entity (stock can be pledged)

Magellan Behavioral Health of Nebraska, LLC

 

X

 

1000799521

 

Magellan Behavioral Health, Inc.

 

LLC

 

100%

 

NE

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

 

Magellan Behavioral Health of Colorado, Inc.

 

 

 

20041307177

 

Magellan Behavioral Health, Inc.

 

Corp

 

100%

 

CO

 

6950 Columbia Gateway Drive
Columbia MD 21046

 

 

Magellan Behavioral Health of Connecticut, LLC

 

 

 

0789504

 

Merit Behavioral Care of Massachusetts, Inc.

 

LLC

 

100%

 

CT

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

Regulated entity (stock can be pledged)

Magellan Behavioral Health of Florida, Inc.

 

 

 

P04000158675

 

Magellan Behavioral Health, Inc.

 

Corp

 

100%

 

FL

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

Regulated entity (stock can be pledged)

Magellan Behavioral Health of Nebraska, LLC

 

X

 

 

 

Magellan Behavioral Health, Inc.

 

LLC

 

100%

 

NE

 

6950 Columbia Gateway Drive
Columbia MD 21046

 

 

Magellan Behavioral Health of New Jersey, LLC (3)

 

 

 

0600112563

 

Green Spring Health Services, Inc.

 

LLC

 

100%

 

NJ

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

Regulated entity (limited liability company interest can be pledged)

Magellan Behavioral Health of Pennsylvania, Inc. (3)

 

 

 

2063574

 

Merit Behavioral Care Corporation

 

Corp.

 

100%

 

PA

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

Regulated entity (stock can be pledged)

Magellan Behavioral Health Providers of Texas, Inc. (4)

 

 

 

0140587101

 

Merit Behavioral Care Corporation

 

Corp.

 

100%

 

TX

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

Non-Profit Entity and Non-Stock Entity (no stock to be pledged)

Magellan Behavioral Health, Inc.

 

X

 

2870663

 

Magellan Health Services, Inc.

 

Corp.

 

100%

 

DE

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

 

Magellan Behavioral of Michigan, Inc.

 

X

 

341839

 

Green Spring Health Services, Inc.

 

Corp.

 

100%

 

MI

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

 

Magellan Behavioral Health Systems, LLC (3)

 

 

 

636259-0160

 

Magellan Behavioral Health, Inc.

 

LLC

 

100%

 

UT

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

Regulated entity (LLC interest can be pledged)

Magellan Capital, Inc.

 

X

 

2855183

 

Magellan Health Services, Inc.

 

Corp.

 

100%

 

DE

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

 

Magellan CBHS Holdings, LLC

 

X

 

2561362

 

Magellan Behavioral Health, Inc.

 

Corp.

 

100%

 

DE

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

 

Magellan Financial Capital Inc.

 

X

 

C30767-2003

 

Magellan Health Services, Inc.

 

Corp.

 

100%

 

NV

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

 

Magellan Health Services of Arizona, Inc.

 

X

 

1156264-7

 

Magellan Behavioral Health, Inc.

 

Corp

 

100%

 

AZ

 

6950 Columbia Gateway Drive
Columbia MD 21046

 

 

Magellan HRSC, Inc.

 

X

 

686314

 

Merit Behavioral Care Corporation

 

Corp.

 

100%

 

OH

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

 

Magellan Sub Co III, Inc.

 

X

 

P07000083835

 

Magellan Health Services, Inc.

 

Corp

 

100%

 

FL

 

6950 Columbia Gateway Drive
Columbia MD 21046

 

 

Managed Care Services Mainstay of Central Pennsylvania, Inc.

 

X

 

987214

 

Green Spring Health Services, Inc.

 

Corp.

 

100%

 

PA

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

 

MBC of America, Inc.

 

X

 

2423978

 

Merit Behavioral Care Corporation

 

Corp.

 

100%

 

DE

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

 

 



 

NAME OF CORPORATION(3)

 

CREDIT
PARTY

 

ORG #

 

OWNER OF STOCK

 

TYPE OF
ORG.

 

% OF
OWNERSHIP

 

STATE
OF
INCORP

 

CORPORATE ADDRESS

 

BASIS FOR WHICH:
A) ANY WHOLLY-
OWNED SPECIFIED
SUBSIDIARY CANNOT
ENTER INTO ANY
CREDIT DOCUMENT OR
B) THE SHARES OF
CAPITAL STOCK OF ANY
DOMESTIC SUBSIDIARY
CANNOT BE PLEDGED
PURSUANT TO THE
PLEDGE AGREEMENT

Magellan Health Services of New Mexico, Inc.

 

X

 

1603315

 

Merit Behavioral Care Corporation

 

Corp.

 

100%

 

NM

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

 

MBC of North Carolina, LLC (3)

 

 

 

0445791

 

Merit Behavioral Care Corporation

 

LLC

 

100%

 

NC

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

Regulated entity (LLC interest can be pledged)

MBH of Puerto Rico, Inc.

 

X

 

n/a

 

Magellan Behavioral Health, Inc.

 

Corp.

 

100%

 

PR

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

Foreign Subsidiary (65% of stock can be pledged)

Merit Behavioral Care Corporation

 

X

 

2329817

 

Magellan Behavioral Health, Inc.

 

Corp.

 

100%

 

DE

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

 

Merit Behavioral Care of Massachusetts, Inc.

 

X

 

043109970

 

Merit Behavioral Care Corporation

 

Corp.

 

100%

 

MA

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

 

Merit Health Insurance Company (3)

 

 

 

00612952 (DOI)

 

Merit Behavioral Care Corporation

 

Corp.

 

100%

 

IL

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

Regulated entity (stock can be pledged)

Montana Community Partners, Inc. (4)

 

 

 

D087912

 

CMG Health, Inc.

 

Corp.

 

55%

 

MT

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

Non-Profit Entity and Non-Stock Entity (no stock to be pledged)

Magellan Life Insurance Company (3)

 

 

 

0923695

 

Merit Health Insurance Company

 

Corp.

 

100%

 

DE

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

Regulated entity (stock cannot be pledged — owned by non-guarantor)

National Imaging Associates, Inc.

 

X

 

2542112

 

Magellan Behavioral Health, Inc.

 

Corp.

 

100%

 

DE

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

 

National Imaging Associates of Pennsylvania, LLC

 

X

 

 

 

National Imaging Associates, Inc.

 

LLC

 

100%

 

PA

 

6950 Columbia Gateway Drive
Columbia MD 21046

 

 

NIA IPA of New York, Inc.

 

 

 

n/a

 

National Imaging Associates, Inc.

 

Corp

 

100%

 

NY

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

Regulated entity (stock can be pledged)

Oncore Healthcare, LLC

 

X

 

4053997

 

ICORE Healthcare, LLC

 

LLC

 

100%

 

DE

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

 

P.P.C., Inc.

 

X

 

00225482

 

Magellan Behavioral Health, Inc.

 

Corp.

 

100%

 

MO

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

 

Personal Performance Consultants of New York, Inc.

 

X

 

n/a

 

P.P.C., Inc.

 

Corp.

 

100%

 

NY

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

 

Plymouth Insurance Company, Ltd. (2)

 

 

 

n/a

 

Magellan CBHS Holdings, LLC

 

Corp.

 

100%

 

Bermuda

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

Foreign Insurance Company (65% of stock can be pledged)

PPC Group, Inc.

 

X

 

2295110

 

Magellan Behavioral Health, Inc.

 

Corp.

 

100%

 

DE

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

 

Premier Holdings, LLC.

 

X

 

314177

 

AdvoCare of Tennessee, Inc.

 

Corp.

 

100%

 

TN

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

 

Premier Behavioral Systems of Tennessee, LLC

 

 

 

0312050

 

Premier Holdings, LLC

 

LLC

 

100%

 

TN

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

Regulated entity (stock can be pledged)

Tennessee Behavioral Health, Inc. (3)

 

 

 

0303280

 

Magellan Behavioral Health, Inc.

 

Corp.

 

100%

 

TN

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

Regulated entity (stock can be pledged)

U.S. IPA Providers, Inc. (3)

 

 

 

n/a

 

AGCA, Inc.

 

Corp.

 

100%

 

NY

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

Regulated entity (stock can be pledged)

Magellan Health Services of California, Inc. — Employer Services (3)

 

 

 

00692186

 

Green Spring Health Services, Inc.

 

Corp.

 

100%

 

CA

 

6950 Columbia Gateway Drive,
Columbia MD 21046

 

Regulated entity (stock cannot be pledged)

 




Exhibit 31.1

 

CERTIFICATIONS

 

I, Rene Lerer, certify that:

 

1.                                       I have reviewed this quarterly report on Form 10-Q of Magellan Health Services, Inc.;

 

2.                                       Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.                                       Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.                                       The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)                                  Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)                                 Designed such control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with generally accepted accounting principles;

 

(c)                                  Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)                                 Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.                                       The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a)                                  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)                                 Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

/s/ RENE LERER

 

Rene Lerer

Date: April 30, 2009

Chief Executive Officer

 

1




Exhibit 31.2

 

CERTIFICATIONS

 

I, Jonathan N. Rubin, certify that:

 

1.                                       I have reviewed this quarterly report on Form 10-Q of Magellan Health Services, Inc.;

 

2.                                       Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.                                       Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.                                       The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)                                  Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)                                 Designed such control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with generally accepted accounting principles;

 

(c)                                  Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)                                 Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.                                       The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a)                                  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)                                 Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

/s/ JONATHAN N. RUBIN

 

Jonathan N. Rubin

Date: April 30, 2009

Chief Financial Officer

 

1




Exhibit 32.1

 

Certification Required by Rule 13a-14(b) and 18 U.S.C. Section 1350

(as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002)

 

I, Rene Lerer, as Chief Executive Officer of Magellan Health Services, Inc (the “Company”), certify, pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002), that to my knowledge:

 

(1)                                  the accompanying Quarterly Report on Form 10-Q of the Company for the quarterly period ended March 31, 2009 (the “Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

(2)                                  the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

/s/ RENE LERER

 

Rene Lerer

Date: April 30, 2009

Chief Executive Officer

 

1




Exhibit 32.2

 

Certification Required by Rule 13a-14(b) and 18 U.S.C. Section 1350

(as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002)

 

I, Jonathan N. Rubin, as Chief Financial Officer of Magellan Health Services, Inc (the “Company”), certify, pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002), that to my knowledge:

 

(1)                                  the accompanying Quarterly Report on Form 10-Q of the Company for the quarterly period ended March 31, 2009 (the “Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

(2)                                  the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

/s/ JONATHAN N. RUBIN

 

Jonathan N. Rubin

Date: April 30, 2009

Chief Financial Officer

 

1